Latest / Clinical Deep Dives / PSYCH 167: Micronutrient Monitoring and Supplementation in Psychiatric Illness

Transcript

PSYCH 167: Micronutrient Monitoring and Supplementation in Psychiatric Illness · Clinical Deep Dives

• 0:00
  SPEAKER_01: Right now,
• 0:00
  SPEAKER_01: one in three adults in the U.S. is, well,
• 0:03
  SPEAKER_01: clinically deficient in a vital neurosteroid,
• 0:06
  SPEAKER_01: a steroid that basically regulates the brain's primary stress response system.
• 0:10
  SPEAKER_01: And another 40% have levels that are entirely insufficient
• 0:13
  SPEAKER_01: to support optimal neurological function.
• 0:16
  SPEAKER_00: It's staggering, really.
• 0:17
  SPEAKER_01: It is.
• 0:18
  SPEAKER_01: Yet, when patients present in clinics with heavy,
• 0:20
  SPEAKER_01: debilitating depression,
• 0:21
  SPEAKER_01: we almost always reach for an SSRI, or,
• 0:24
  SPEAKER_01: you know,
• 0:25
  SPEAKER_01: an SNRI,
• 0:25
  SPEAKER_01: before we ever think to check their blood for this basic structural building block.
• 0:29
  SPEAKER_00: It's a profound oversight.
• 0:30
  SPEAKER_01: It is.
• 0:51
  SPEAKER_00: Exactly.
• 0:52
  SPEAKER_00: And you cannot fully understand how the process goes wrong if you are ignoring
• 0:57
  SPEAKER_00: the biological raw materials required to make the machine run in the first place.
• 1:01
  SPEAKER_01: Which is exactly why we are opening this particular dossier today.
• 1:04
  SPEAKER_01: We are taking a deep dive into Chapter 30.5 of Kaplan
• 1:08
  SPEAKER_01: and Sadoch's comprehensive textbook of psychiatry.
• 1:12
  SPEAKER_00: A dense chapter, but an important one.
• 1:15
  SPEAKER_01: It's titled Micronutrient Monitoring and Supplementation in Psychiatric Illness.
• 1:20
  SPEAKER_01: But I want to be incredibly clear about our mission today for you listening.
• 1:25
  SPEAKER_01: We are not just going to read you tables of epidemiological data.
• 1:30
  SPEAKER_00: No, absolutely not.
• 1:30
  SPEAKER_00: Nobody retains information that way.
• 1:32
  SPEAKER_01: Right.
• 1:32
  SPEAKER_01: Far from it.
• 1:34
  SPEAKER_00: Our goal here is conceptual synthesis.
• 1:37
  SPEAKER_00: We want to build robust, lasting mental models for you.
• 1:41
  SPEAKER_00: We need to clarify the actual biological mechanisms at play beneath the surface.
• 1:46
  SPEAKER_00: And most importantly, strengthen your clinical reasoning.
• 1:50
  SPEAKER_01: Because whether you are a psychiatry trainee,
• 1:52
  SPEAKER_01: a seasoned clinician,
• 1:54
  SPEAKER_01: or just a highly motivated student of the mind, you need to understand this.
• 1:59
  SPEAKER_00: Spot on.
• 2:00
  SPEAKER_00: We need to move beyond mere association,
• 2:03
  SPEAKER_00: which is everywhere in the wellness space right now,
• 2:06
  SPEAKER_00: and step firmly into the realm of causation and clinical utility.
• 2:11
  SPEAKER_01: Yeah, that distinction between association and causation is where I actually want
• 2:16
  SPEAKER_01: to plant my first flag,
• 2:17
  SPEAKER_01: because there is this massive cultural phenomenon right now regarding nutritional
• 2:22
  SPEAKER_01: psychiatry.
• 2:23
  SPEAKER_00: There really is.
• 2:23
  SPEAKER_01: Yeah.
• 2:24
  SPEAKER_00: It's a pervasive narrative.
• 2:26
  SPEAKER_01: If we constantly hear that low vitamins equal bad mental health,
• 2:30
  SPEAKER_01: Why shouldn't we just prescribe a high quality,
• 2:32
  SPEAKER_01: broad spectrum multivitamin to every single patient who walks through
• 2:35
  SPEAKER_01: the clinic door?
• 2:36
  SPEAKER_01: I mean, it seems harmless, right?
• 2:37
  SPEAKER_01: Potentially beneficial.
• 2:39
  SPEAKER_00: Well, it seems harmless, but it's the trap of treating the spreadsheet instead of the patient.
• 2:44
  SPEAKER_01: Treating the spreadsheet.
• 2:46
  SPEAKER_00: Yeah.
• 2:46
  SPEAKER_00: Let's say an observational epidemiological study shows that a population of people
• 2:52
  SPEAKER_00: with major depressive disorder tends to have low levels of a certain vitamin.
• 2:56
  SPEAKER_00: That is an inverse association.
• 2:58
  SPEAKER_00: But the critical question remains, did the low vitamin cause the depression?
• 3:04
  SPEAKER_01: Or did the severe depression cause the person to experience profound anhedonia?
• 3:08
  SPEAKER_00: Exactly.
• 3:09
  SPEAKER_00: Did they stop eating a balanced diet,
• 3:11
  SPEAKER_00: stop leaving their house,
• 3:12
  SPEAKER_00: stop engaging in self-care, which subsequently led to the low vitamin?
• 3:17
  SPEAKER_01: Ah, the classic chicken and egg scenario.
• 3:20
  SPEAKER_01: The depression could actually be the driver of the deficiency and not the other way around.
• 3:24
  SPEAKER_00: Precisely.
• 3:25
  SPEAKER_00: And if you just throw a generic multivitamin at that patient without understanding
• 3:29
  SPEAKER_00: the mechanism,
• 3:30
  SPEAKER_00: you might simply be correcting a downstream metabolic effect of the illness.
• 3:34
  SPEAKER_01: Without ever touching the root neurobiological cause.
• 3:38
  SPEAKER_00: Right.
• 3:38
  SPEAKER_00: Furthermore, indiscriminate supplementation is not just a harmless placebo.
• 3:43
  SPEAKER_00: It adds unnecessary financial burden to the patient.
• 3:46
  SPEAKER_00: It can introduce dangerous adverse side effects if fat-soluble vitamins accumulate.
• 3:50
  SPEAKER_01: Which we'll get into.
• 3:51
  SPEAKER_00: We will.
• 3:52
  SPEAKER_00: And worst of all,
• 3:53
  SPEAKER_00: focusing on the quote unquote miracle supplement can significantly delay
• 3:57
  SPEAKER_00: the implementation of genuinely effective evidence based psychiatric treatments.
• 4:02
  SPEAKER_01: So to navigate this complex landscape safely,
• 4:05
  SPEAKER_01: we need a solid core conceptual framework before we even examine the first nutrient.
• 4:10
  SPEAKER_00: We do.
• 4:11
  SPEAKER_01: And our first boundary is defining exactly who we are talking about today.
• 4:15
  SPEAKER_01: This deep dive focuses strictly on treating individuals
• 4:18
  SPEAKER_01: with established psychiatric illness or clinically significant symptoms.
• 4:23
  SPEAKER_00: That is a vital boundary.
• 4:25
  SPEAKER_00: We are explicitly excluding the prevention of illness.
• 4:28
  SPEAKER_01: Because prevention is a totally different biochemical and statistical ballgame, right?
• 4:32
  SPEAKER_00: Entirely different.
• 4:33
  SPEAKER_00: We are also explicitly excluding peripartum conditions,
• 4:37
  SPEAKER_00: trauma-related disorders,
• 4:38
  SPEAKER_00: obsessive-compulsive disorders, and substance use disorders.
• 4:43
  SPEAKER_00: Today,
• 4:43
  SPEAKER_00: we are focusing our clinical lens on standard common psychiatric presentations,
• 4:48
  SPEAKER_00: major depression, ADHD, schizophrenia, and cognitive decline.
• 4:53
  SPEAKER_01: Okay, boundaries set.
• 4:55
  SPEAKER_01: We are treating sick patients, not trying to biohack or optimize healthy ones.
• 4:59
  SPEAKER_00: Exactly.
• 5:00
  SPEAKER_01: Now, what is the standard of evidence we are holding these interventions to?
• 5:03
  SPEAKER_01: Because,
• 5:04
  SPEAKER_01: as you mentioned,
• 5:04
  SPEAKER_01: epidemiological surveys showing Group A eats more salmon
• 5:08
  SPEAKER_01: and reports less sadness are virtually useless
• 5:11
  SPEAKER_01: for guiding specific treatment protocols.
• 5:13
  SPEAKER_00: Totally useless for the individual patient.
• 5:16
  SPEAKER_00: To prescribe something responsibly in psychiatry,
• 5:18
  SPEAKER_00: we must rely almost exclusively on meta-analyses
• 5:22
  SPEAKER_00: of placebo-controlled randomized control trials, RCTs.
• 5:26
  SPEAKER_01: The gold standard.
• 5:27
  SPEAKER_00: The gold standard.
• 5:28
  SPEAKER_00: We need to see what happens when researchers isolate the specific variable, the single nutrient.
• 5:34
  SPEAKER_00: Give it to a symptomatic patient and compare their trajectory to a patient receiving
• 5:38
  SPEAKER_00: an identical dummy pill.
• 5:40
  SPEAKER_00: We have to strip away the placebo effect,
• 5:42
  SPEAKER_00: the natural course of the illness, and confirmation bias.
• 5:45
  SPEAKER_01: But even when we look at rigorous RCTs, we need a way to measure reality.
• 5:50
  SPEAKER_01: I mean,
• 5:50
  SPEAKER_01: we need to know not just if an intervention is statistically separated from placebo,
• 5:54
  SPEAKER_01: but how well it worked.
• 5:56
  SPEAKER_00: Right.
• 5:57
  SPEAKER_00: Because a statistically significant finding could still mean
• 6:00
  SPEAKER_00: a practically invisible change in the patient's daily life.
• 6:03
  SPEAKER_01: Right.
• 6:04
  SPEAKER_01: So we need to talk about effect sizes.
• 6:06
  SPEAKER_00: Yes.
• 6:07
  SPEAKER_00: In the medical literature,
• 6:08
  SPEAKER_00: to quantify the magnitude of benefit a treatment provides over a placebo,
• 6:12
  SPEAKER_00: we use a metric called Cohen's D.
• 6:14
  SPEAKER_01: Which is often reported as the standardized mean difference, right?
• 6:17
  SPEAKER_01: The SMD?
• 6:18
  SPEAKER_00: That's the one.
• 6:19
  SPEAKER_00: I want to establish the benchmark numbers right now so you can hold them
• 6:22
  SPEAKER_00: in your mind as we walk through the biology later.
• 6:24
  SPEAKER_01: Let's define the scale for the listener.
• 6:26
  SPEAKER_00: Okay, in terms of the standardized mean difference,
• 6:29
  SPEAKER_00: an SMD of 0.2 is considered a small effect size.
• 6:33
  SPEAKER_01: 0.2 is small.
• 6:35
  SPEAKER_00: An SMD of 0.5 is a moderate effect size.
• 6:38
  SPEAKER_00: An SMD greater than 0.8 is considered a large effect size.
• 6:43
  SPEAKER_00: And an SMD of 1.3 or greater is a very large effect size.
• 6:48
  SPEAKER_01: Okay, got it.
• 6:48
  SPEAKER_01: 0.2, 0.5, 0.8, 1.3.
• 6:51
  SPEAKER_01: But numbers are great for papers.
• 6:53
  SPEAKER_01: They can be a bit abstract in the clinic.
• 6:56
  SPEAKER_01: We need a clinical anchor.
• 6:57
  SPEAKER_01: How do those standard mean differences compare to the heavy hitters
• 7:01
  SPEAKER_01: of standard psychiatric treatment?
• 7:02
  SPEAKER_01: Like, let's take major depressive disorder as our baseline.
• 7:05
  SPEAKER_00: Good idea.
• 7:07
  SPEAKER_00: Let's look at the cornerstone pharmacological treatments.
• 7:10
  SPEAKER_00: Standard antidepressant medications,
• 7:11
  SPEAKER_00: your SSRIs or your SNRIs,
• 7:15
  SPEAKER_00: generally sit at an SMD of somewhere between 0.19 and 0.62.
• 7:20
  SPEAKER_01: Oh, wow.
• 7:21
  SPEAKER_00: Yeah, depending on the specific drug, the severity of the population, the length of the trial.
• 7:26
  SPEAKER_00: So we are looking at small to moderate effect sizes for our primary frontline medications.
• 7:31
  SPEAKER_01: That is really fascinating context.
• 7:34
  SPEAKER_01: And what about the more aggressive interventions for treatment-resistant depression?
• 7:38
  SPEAKER_00: Well, transcranial magnetic stimulation, or TMS,
• 7:42
  SPEAKER_00: where we use magnetic fields to stimulate nerve cells,
• 7:45
  SPEAKER_00: that hits around an SMD of 1.33%.
• 7:49
  SPEAKER_01: So that's very large.
• 7:50
  SPEAKER_00: Very large.
• 7:51
  SPEAKER_00: And electroconvulsive therapy, ECT,
• 7:54
  SPEAKER_00: which involves inducing a brief seizure to reset neural firing patterns,
• 7:58
  SPEAKER_00: that yields a massive SMD of 2.83.
• 8:00
  SPEAKER_00: 2.83.
• 8:00
  SPEAKER_01: Okay, that paints a remarkably vivid picture.
• 8:06
  SPEAKER_01: Let's use a metaphor here.
• 8:08
  SPEAKER_01: If an SMD of 0.2 is like turning on a small desk lamp in a dark room, I mean,
• 8:12
  SPEAKER_01: it helps you see the paper in front of you,
• 8:13
  SPEAKER_01: but the corners of the room are still in shadow, right?
• 8:16
  SPEAKER_01: Then ECT at 2.83 is like turning on stadium floodlights.
• 8:21
  SPEAKER_01: It completely illuminates everything.
• 8:23
  SPEAKER_00: I love that analogy.
• 8:25
  SPEAKER_01: So as we walk through this laboratory of missing elements today,
• 8:28
  SPEAKER_01: we need to constantly ask ourselves,
• 8:30
  SPEAKER_01: are these vitamins desk lamps or are they floodlights?
• 8:34
  SPEAKER_00: That is the exact analytical mindset we need.
• 8:37
  SPEAKER_00: And with that framework established,
• 8:39
  SPEAKER_00: let us tackle the neurosteroid you mentioned in your opening hook,
• 8:42
  SPEAKER_00: vitamin D.
• 8:43
  SPEAKER_01: Let's do it.
• 8:45
  SPEAKER_01: And I'll reiterate my opening thought because vitamin D is an absolute paradox.
• 8:49
  SPEAKER_01: Calling it a vitamin is actually a historical misnomer, isn't it?
• 8:53
  SPEAKER_00: It is entirely a misnomer.
• 8:55
  SPEAKER_00: A true vitamin is an essential micronutrient that the organism cannot synthesize
• 9:00
  SPEAKER_00: in sufficient quantities and therefore must obtain through the diet.
• 9:03
  SPEAKER_01: Like vitamin C. Exactly.
• 9:05
  SPEAKER_00: If we don't eat vitamin C, we get scurvy.
• 9:08
  SPEAKER_00: Vitamin D, however, is a fat-soluble steroid hormone.
• 9:12
  SPEAKER_01: A hormone?
• 9:13
  SPEAKER_00: Yes.
• 9:14
  SPEAKER_00: What makes it unique is that we synthesize it endogenously.
• 9:18
  SPEAKER_00: Our own bodies manufacture it from cholesterol.
• 9:20
  SPEAKER_00: But we require ultraviolet B light from the sun hitting our skin to provide
• 9:25
  SPEAKER_00: the energy to kickstart that chemical conversion.
• 9:28
  SPEAKER_01: We literally photosynthesize this crucial hormone?
• 9:31
  SPEAKER_00: We do.
• 9:32
  SPEAKER_01: But...
• 9:32
  SPEAKER_01: What is a fat soluble steroid hormone actually doing in the architecture of the brain?
• 9:37
  SPEAKER_01: Why does psychiatry care about something that's traditionally associated with,
• 9:41
  SPEAKER_01: you know, bone density and rickets?
• 9:43
  SPEAKER_00: Because the central nervous system is absolutely teeming with vitamin D receptors,
• 9:48
  SPEAKER_00: particularly in areas like the hippocampus,
• 9:50
  SPEAKER_00: the prefrontal cortex, and the substantia nigra.
• 9:53
  SPEAKER_01: All the heavy hitting psychiatric zones.
• 9:55
  SPEAKER_00: Precisely.
• 9:56
  SPEAKER_00: And the mechanisms are vast.
• 9:58
  SPEAKER_00: Firstly,
• 9:59
  SPEAKER_00: it supports basic neurodevelopment and neurogenesis,
• 10:02
  SPEAKER_00: the actual growth and survival of new neurons.
• 10:04
  SPEAKER_01: How does it do that?
• 10:06
  SPEAKER_00: It upregulates the production of neurotrophic factors,
• 10:09
  SPEAKER_00: like brain-derived neurotrophic factor,
• 10:11
  SPEAKER_00: or BDNF, which acts like fertilizer for the brain.
• 10:15
  SPEAKER_01: So it's keeping the physical structure of the brain robust.
• 10:18
  SPEAKER_01: What about the chemical signaling?
• 10:20
  SPEAKER_00: It is deeply involved in the synthesis of neurotransmitters.
• 10:24
  SPEAKER_00: It activates the expression of the gene that encodes for tyrosine hydroxylase.
• 10:28
  SPEAKER_01: And what does that enzyme do?
• 10:30
  SPEAKER_00: That is the rate-limiting enzyme in the production of dopamine, norepinephrine, and epinephrine.
• 10:35
  SPEAKER_00: Without sufficient vitamin D, that entire catecholamine synthesis pathway just throttles down.
• 10:40
  SPEAKER_01: Wow.
• 10:42
  SPEAKER_00: Furthermore,
• 10:42
  SPEAKER_00: it provides profound immune modulation and anti-inflammatory actions within
• 10:46
  SPEAKER_00: the central nervous system, calming down microglial activation.
• 10:50
  SPEAKER_01: I want to pause on the immune modulation because inflammation
• 10:53
  SPEAKER_01: in psychiatry is becoming an unavoidable topic.
• 10:56
  SPEAKER_01: But you also mentioned earlier that it regulates the HPA axis.
• 11:00
  SPEAKER_01: Walk us through that mechanism.
• 11:02
  SPEAKER_00: The HPA axis,
• 11:04
  SPEAKER_00: the hypothalamic-pituitary-adrenal axis,
• 11:07
  SPEAKER_00: is your body's primary stress response system.
• 11:10
  SPEAKER_00: When you perceive a threat,
• 11:11
  SPEAKER_00: your hypothalamus releases hormones that eventually signal your adrenal glands
• 11:15
  SPEAKER_00: to pump out cortisol.
• 11:17
  SPEAKER_00: The stress hormone.
• 11:18
  SPEAKER_00: Right.
• 11:19
  SPEAKER_00: In a healthy system, there's a negative feedback loop.
• 11:22
  SPEAKER_00: The cortisol eventually tells the brain to shut the alarm off.
• 11:25
  SPEAKER_01: Makes sense.
• 11:26
  SPEAKER_00: But in chronic depression and chronic trauma, that axis becomes hyperactive and deregulated.
• 11:32
  SPEAKER_00: The alarm never shuts off, and chronic cortisol is neurotoxic.
• 11:35
  SPEAKER_00: It literally shrinks the hippocampus.
• 11:38
  SPEAKER_01: And where does vitamin D intervene in that destructive loop?
• 11:41
  SPEAKER_00: Vitamin D binds to glucocorticoid receptors in the hippocampus and acts as a stabilizer.
• 11:48
  SPEAKER_00: It enhances that negative feedback loop,
• 11:50
  SPEAKER_00: effectively helping the brain to hear the shut off signal more clearly,
• 11:54
  SPEAKER_00: thereby dampening the hyperactive stress response.
• 11:57
  SPEAKER_01: That is an incredibly busy foundational molecule.
• 12:01
  SPEAKER_01: I mean, it's fertilizer,
• 12:02
  SPEAKER_01: it's a factory form for dopamine,
• 12:04
  SPEAKER_01: it's an anti-inflammatory, and it's a stress access stabilizer.
• 12:08
  SPEAKER_00: Wears a lot of hats.
• 12:10
  SPEAKER_01: So if we want to measure it in a patient,
• 12:12
  SPEAKER_01: what are the biomarkers we are looking for and who is actually at risk
• 12:17
  SPEAKER_01: of lacking it?
• 12:18
  SPEAKER_00: Well, clinically, we do not measure the active form of the hormone.
• 12:21
  SPEAKER_00: We measure a precursor metabolite called serum 25-hydroxyvitamin D.
• 12:26
  SPEAKER_01: You'll see it written on lab reports as 25-OHD, right?
• 12:30
  SPEAKER_00: Yes, exactly.
• 12:32
  SPEAKER_00: We use this specific metabolite because it has
• 12:34
  SPEAKER_00: a relatively long biological half-life of about 15 days in the bloodstream.
• 12:39
  SPEAKER_01: Why does the 15-day half-life make it the preferred test?
• 12:42
  SPEAKER_00: Because it gives us a stable, smoothed out reflection of the patient's true status.
• 12:47
  SPEAKER_00: It accounts for both what their skin has produced from recent sun exposure
• 12:50
  SPEAKER_00: and what their gut has absorbed from food or supplements over the past few weeks.
• 12:54
  SPEAKER_01: Oh, I see.
• 12:55
  SPEAKER_00: Yeah.
• 12:55
  SPEAKER_00: If we measured the fully active form calcitriol,
• 12:58
  SPEAKER_00: we'd get a snapshot that fluctuates wildly by the hour,
• 13:02
  SPEAKER_00: which is completely useless for determining baseline nutritional status.
• 13:06
  SPEAKER_01: That makes perfect sense.
• 13:07
  SPEAKER_01: And the cutoffs.
• 13:08
  SPEAKER_01: At what threshold does a clinician need to intervene?
• 13:11
  SPEAKER_00: The generally accepted endocrine society guidelines dictate that
• 13:15
  SPEAKER_00: a serum level greater than 75 nanomoles per liter,
• 13:18
  SPEAKER_00: which is 30 nanograms per milliliter, is considered sufficient for optimal health.
• 13:23
  SPEAKER_01: Okay.
• 13:23
  SPEAKER_01: Greater than 75 is sufficient.
• 13:25
  SPEAKER_00: Right.
• 13:26
  SPEAKER_00: A level between 50 and 70 nanomoles per liter is termed insufficient.
• 13:31
  SPEAKER_00: And anything under 50 nanomoles per liter,
• 13:33
  SPEAKER_00: less than 20 nanograms per milliliter, is classified as a true clinical deficiency.
• 13:39
  SPEAKER_01: And this is where the demographics get alarming, leading back to my opening point.
• 13:43
  SPEAKER_01: Because of modern sedentary indoor lifestyles
• 13:46
  SPEAKER_01: and entirely valid dermatological efforts to limit sun exposure to prevent melanoma,
• 13:51
  SPEAKER_01: deficiency is rampant.
• 13:53
  SPEAKER_00: It truly is an epidemic.
• 13:55
  SPEAKER_01: According to the epidemiological data,
• 13:57
  SPEAKER_01: one in three U.S.
• 13:58
  SPEAKER_01: adults is clinically deficient,
• 14:00
  SPEAKER_01: under that 15 nanomoles per liter mark,
• 14:02
  SPEAKER_01: and another 40% sit in the insufficient range.
• 14:06
  SPEAKER_00: Which means nearly three quarters of the population are walking around with
• 14:09
  SPEAKER_00: a compromised supply of this vital neurosteroid.
• 14:12
  SPEAKER_01: Exactly.
• 14:13
  SPEAKER_01: And certain populations carry much higher biological risk factors, don't they?
• 14:16
  SPEAKER_00: Yes, they do.
• 14:17
  SPEAKER_00: Individuals with darker pigmented skin are at significantly higher risk
• 14:22
  SPEAKER_00: because melanin,
• 14:23
  SPEAKER_00: which is nature's brilliant sunscreen,
• 14:25
  SPEAKER_00: naturally absorbs and blocks the specific UVB radiation needed to trigger
• 14:30
  SPEAKER_00: the synthesis.
• 14:30
  SPEAKER_01: Right.
• 14:31
  SPEAKER_01: Right.
• 14:32
  SPEAKER_00: So in higher latitudes,
• 14:33
  SPEAKER_00: particularly during winter,
• 14:34
  SPEAKER_00: individuals with dark skin may produce almost zero endogenous vitamin D.
• 14:40
  SPEAKER_00: Older age is another factor,
• 14:42
  SPEAKER_00: as the skin's capacity to synthesize the precursor diminishes remarkably over
• 14:46
  SPEAKER_00: the decades.
• 14:47
  SPEAKER_01: Now I notice in the sources that obesity is also listed as a primary risk factor.
• 14:51
  SPEAKER_01: That seems counterintuitive.
• 14:53
  SPEAKER_01: I would assume diet plays a role there, but is there a mechanical reason?
• 14:57
  SPEAKER_00: There is a purely mechanical lipophilic reason.
• 15:01
  SPEAKER_00: Remember, vitamin D is a fat-soluble hormone.
• 15:03
  SPEAKER_01: Right, fat-soluble.
• 15:05
  SPEAKER_00: In individuals with a high body mass index and higher volumes of adipose tissue,
• 15:09
  SPEAKER_00: the vitamin D that is produced or ingested gets sequestered.
• 15:13
  SPEAKER_00: It gets locked away deep inside the fat cells.
• 15:16
  SPEAKER_01: It effectively becomes trapped.
• 15:17
  SPEAKER_00: Trapped, exactly.
• 15:19
  SPEAKER_00: The total body store might actually be quite high,
• 15:22
  SPEAKER_00: but the amount circulating freely in the bloodstream,
• 15:24
  SPEAKER_00: the amount available to cross the blood-brain barrier and bathe the neurons,
• 15:28
  SPEAKER_00: is drastically reduced.
• 15:29
  SPEAKER_01: So the brain is starving while the body storage vaults are completely full.
• 15:32
  SPEAKER_00: It's a cruel irony, yes.
• 15:35
  SPEAKER_01: What about pharmacological risk factors?
• 15:36
  SPEAKER_01: Do standard medications interfere with this?
• 15:38
  SPEAKER_00: They can, yes.
• 15:40
  SPEAKER_00: Chronic use of certain medications,
• 15:41
  SPEAKER_00: particularly hepatic enzyme-inducing anticonvulsants like carbamazepine or phenytoin
• 15:49
  SPEAKER_00: and long-term glucocorticoids,
• 15:51
  SPEAKER_00: will rapidly accelerate the catabolism or the breakdown of vitamin D,
• 15:56
  SPEAKER_00: leading to severe deficiencies if not closely monitored.
• 15:59
  SPEAKER_01: Okay, so we have a vital hormone,
• 16:01
  SPEAKER_01: a massive population deficiency, and a clear mechanistic link to brain function.
• 16:06
  SPEAKER_01: Let's look at the clinical manifestations in psychiatry.
• 16:10
  SPEAKER_01: Let's look at the first major trial data for depression.
• 16:12
  SPEAKER_01: What actually happens when we test vitamin D against placebo in an RCT?
• 16:17
  SPEAKER_00: We can look to a rigorous meta-analysis of four RCTs,
• 16:21
  SPEAKER_00: encompassing 948 adults with established unipolar major depressive disorder.
• 16:27
  SPEAKER_00: They investigated whether adding vitamin D improved their outcomes.
• 16:31
  SPEAKER_00: And?
• 16:31
  SPEAKER_00: And the results showed
• 16:33
  SPEAKER_00: that vitamin D supplementation improved depressive symptom scores with
• 16:37
  SPEAKER_00: a moderate effect size.
• 16:39
  SPEAKER_00: The standardized mean difference was .58.
• 16:42
  SPEAKER_01: Wait, .58?
• 16:44
  SPEAKER_01: If we refer back to our clinical anchor,
• 16:47
  SPEAKER_01: standard SSRI and SNRI antidepressants generally sit between .19 and .62.
• 16:54
  SPEAKER_01: An SMD of 0.58 puts vitamin D right in the mix with frontline pharmacological treatments.
• 17:00
  SPEAKER_00: It really does.
• 17:01
  SPEAKER_01: That is a very bright desk lamp.
• 17:03
  SPEAKER_01: Maybe even a small floor lamp illuminating the room.
• 17:06
  SPEAKER_00: It is a highly significant finding,
• 17:08
  SPEAKER_00: especially considering the benign safety profile compared to psychotropics.
• 17:12
  SPEAKER_00: The supplementation strategies in these trials varied wildly, though.
• 17:16
  SPEAKER_00: Some used a daily dose of 1,500 international units.
• 17:21
  SPEAKER_00: Others used a massive weekly bolus of 50,000 IU.
• 17:24
  SPEAKER_01: And how long were the trials?
• 17:26
  SPEAKER_00: The study durations stretched anywhere from 8 to 52 weeks.
• 17:30
  SPEAKER_00: Crucially, no significant adverse events were reported across these treatment arms.
• 17:35
  SPEAKER_00: So on the surface, it looks like a fantastic, universally applicable adjunctive intervention.
• 17:41
  SPEAKER_01: But there has to be a catch.
• 17:43
  SPEAKER_01: I mean, there has to be a biological nuance we are missing
• 17:47
  SPEAKER_01: if it isn't just universally prescribed to everyone with low mood.
• 17:51
  SPEAKER_00: There is a massive nuance.
• 17:53
  SPEAKER_00: And it becomes glaringly obvious when we look at the meta-analyses for
• 17:57
  SPEAKER_00: the second psychiatric condition associated with this hormone,
• 18:01
  SPEAKER_00: ADHD in children and adolescents.
• 18:04
  SPEAKER_01: Right.
• 18:04
  SPEAKER_01: Let's break down the ADHD data.
• 18:06
  SPEAKER_01: We have a meta-analysis of four RCTs, 256 children aged 2 to 18.
• 18:13
  SPEAKER_01: All of these children were actively taking methylphenidate,
• 18:16
  SPEAKER_01: a standard stimulant medication for their ADHD.
• 18:18
  SPEAKER_00: Yes.
• 18:19
  SPEAKER_01: The researchers added vitamin D as an adjunct to see if it boosted the efficacy.
• 18:24
  SPEAKER_01: The overall effect size for total ADHD symptom scores was small, an SMD of 0.39.
• 18:30
  SPEAKER_01: But when they broke it down by specific symptom domains, it was much stronger.
• 18:34
  SPEAKER_00: It was.
• 18:34
  SPEAKER_01: Inattention had a medium effect size of 0.67, and hyperactivity showed an SMD of 0.60.
• 18:41
  SPEAKER_00: Those are genuinely impressive numbers for a simple adjunct to a powerful stimulant.
• 18:45
  SPEAKER_00: But here is where we find our crucial clue.
• 18:49
  SPEAKER_00: In that ADHD meta-analysis,
• 18:51
  SPEAKER_00: the researchers actually performed a subgroup analysis based on
• 18:54
  SPEAKER_00: the patient's baseline vitamin D levels before the intervention started.
• 18:57
  SPEAKER_01: Meaning they separated the data to see who was actually deficient
• 19:01
  SPEAKER_01: before they started handing out the pills.
• 19:02
  SPEAKER_00: Exactly.
• 19:04
  SPEAKER_00: And what they found dictates how we must view this entire field of nutritional psychiatry.
• 19:09
  SPEAKER_00: The children who had deficient or insufficient vitamin D levels
• 19:12
  SPEAKER_00: at baseline improved significantly with the supplementation.
• 19:16
  SPEAKER_01: And the children who already had adequate levels?
• 19:19
  SPEAKER_00: The children who already had adequate healthy baseline levels did not improve at all.
• 19:24
  SPEAKER_00: Their symptom trajectories were identical to the placebo group.
• 19:28
  SPEAKER_01: So it wasn't the vitamin D acting as a magical broad spectrum psychiatric drug
• 19:33
  SPEAKER_01: that treats the pathology of ADHD.
• 19:36
  SPEAKER_01: It was the vitamin D acting as a missing structural element.
• 19:40
  SPEAKER_00: Precisely.
• 19:41
  SPEAKER_01: If your house is missing bricks and the foundation is sagging,
• 19:45
  SPEAKER_01: bringing a pallet of bricks fixes the house.
• 19:47
  SPEAKER_01: But if your house already has all of its structural bricks in place,
• 19:51
  SPEAKER_01: dumping a pile of extra bricks on the front lawn doesn't make the house any stronger
• 19:54
  SPEAKER_01: or function any better.
• 19:55
  SPEAKER_00: That is a wonderful, highly accurate analogy.
• 19:59
  SPEAKER_00: You cannot out-supplement an adequate baseline.
• 20:02
  SPEAKER_00: And this leads to a very specific, uncompromising clinical formula for psychiatric practice.
• 20:07
  SPEAKER_01: Let's hear it.
• 20:09
  SPEAKER_00: Leads to a possible contribution to the psychiatric symptoms.
• 20:13
  SPEAKER_00: You must test to confirm the physiological reality.
• 20:16
  SPEAKER_00: If low, you correct the deficiency.
• 20:19
  SPEAKER_00: Then and only then do you reassess the psychiatric symptoms
• 20:23
  SPEAKER_00: to see what underlying pathology remains.
• 20:26
  SPEAKER_01: Test, correct, reassess.
• 20:28
  SPEAKER_01: You cannot just guess based on an epidemiological hunch.
• 20:32
  SPEAKER_00: You absolutely cannot guess because vitamin D is fat soluble.
• 20:36
  SPEAKER_00: Unlike water-soluble vitamins where you just excrete the excess in your urine,
• 20:41
  SPEAKER_00: fat-soluble vitamins accumulate relentlessly in the liver and adipose tissue.
• 20:46
  SPEAKER_01: Right.
• 20:46
  SPEAKER_00: If you blindly give high therapeutic doses of vitamin D to a patient
• 20:50
  SPEAKER_00: who doesn't need it, you risk severe toxicity.
• 20:53
  SPEAKER_00: The primary danger is hypercalcemia,
• 20:55
  SPEAKER_00: dangerously high levels of calcium in the blood,
• 20:58
  SPEAKER_00: which can cause severe confusion,
• 21:00
  SPEAKER_00: massive kidney stones, and potentially fatal cardiac arrhythmias.
• 21:04
  SPEAKER_01: So you must test first.
• 21:06
  SPEAKER_00: You must test first.
• 21:08
  SPEAKER_00: And if they are deficient,
• 21:09
  SPEAKER_00: you follow the established Endocrine Society guidelines for repletion,
• 21:13
  SPEAKER_00: which usually involves a high dose loading phase to fill the vaults,
• 21:16
  SPEAKER_00: followed by a lower daily maintenance dose.
• 21:19
  SPEAKER_01: So the synthesis of this first station in our laboratory is profound.
• 21:23
  SPEAKER_01: Treating a genuine biological deficiency is entirely different from prescribing
• 21:28
  SPEAKER_01: a vitamin as a psychiatric medicine.
• 21:30
  SPEAKER_01: The nuance, the real medical detective work, is in the baseline testing.
• 21:35
  SPEAKER_00: Precisely.
• 21:36
  SPEAKER_00: If a patient is severely depressed and happens
• 21:38
  SPEAKER_00: to also be severely vitamin D deficient,
• 21:42
  SPEAKER_00: replenishing that vitamin is just good basic internal medicine.
• 21:46
  SPEAKER_01: Will it cure their depression entirely?
• 21:48
  SPEAKER_00: Perhaps not.
• 21:50
  SPEAKER_00: The psychosocial factors, the trauma, the genetic predispositions remain.
• 21:54
  SPEAKER_00: But correcting the deficiency removes a heavy,
• 21:56
  SPEAKER_00: invisible biological weight that was suppressing their neurogenesis
• 22:01
  SPEAKER_00: and making it infinitely harder for their brain to recover.
• 22:04
  SPEAKER_01: Beautifully synthesized.
• 22:05
  SPEAKER_01: All right,
• 22:05
  SPEAKER_01: let's pivot from the fat soluble hormones regulating the brain to
• 22:09
  SPEAKER_01: the water soluble vitamins that actually wire it.
• 22:12
  SPEAKER_01: Let's examine vitamin B12.
• 22:14
  SPEAKER_00: B12 or cobalamin.
• 22:16
  SPEAKER_00: This is a fascinating molecule.
• 22:19
  SPEAKER_00: Unlike vitamin D, this is a true water soluble vitamin.
• 22:23
  SPEAKER_00: It is synthesized exclusively by certain bacteria and archaea and it accumulates in
• 22:28
  SPEAKER_00: the food chain.
• 22:30
  SPEAKER_01: Right.
• 22:30
  SPEAKER_00: Therefore,
• 22:31
  SPEAKER_00: for humans,
• 22:32
  SPEAKER_00: it is found naturally almost exclusively in animal products,
• 22:35
  SPEAKER_00: meat, fish, eggs, dairy.
• 22:38
  SPEAKER_00: And it is absolutely vital for normal neuronal function,
• 22:42
  SPEAKER_00: particularly the creation and maintenance of the myelin sheath.
• 22:45
  SPEAKER_01: What exactly is the myelin sheath for those who might need a neuroanatomy refresher?
• 22:49
  SPEAKER_00: Think of the myelin sheath as
• 22:51
  SPEAKER_00: the highly specialized fatty insulation wrapped tightly around the axons
• 22:54
  SPEAKER_00: of our neurons.
• 22:56
  SPEAKER_00: It acts exactly like the rubber coating on the electrical wires in your house.
• 23:00
  SPEAKER_01: Okay.
• 23:00
  SPEAKER_00: It prevents the electrical signal from leaking out,
• 23:03
  SPEAKER_00: and it allows for something called saltatory conduction,
• 23:07
  SPEAKER_00: where the electrical impulse literally jumps rapidly from node to node along
• 23:11
  SPEAKER_00: the nerve.
• 23:12
  SPEAKER_00: Without sufficient B12, the myelin sheath degrades.
• 23:17
  SPEAKER_01: The insulation frays.
• 23:18
  SPEAKER_00: The insulation frays.
• 23:19
  SPEAKER_00: The electrical signals slow down, misfire, or short circuit entirely.
• 23:24
  SPEAKER_01: So if vitamin D is a steroid hormone managing the factory environment,
• 23:29
  SPEAKER_01: B12 is the rubber coating on the electrical wires of the brain.
• 23:32
  SPEAKER_01: If you lack it, things start to glitch.
• 23:34
  SPEAKER_00: That's a very accurate visualization.
• 23:38
  SPEAKER_00: And historically, the medical profession learned about this the hard way.
• 23:43
  SPEAKER_00: Severe, prolonged B12 deficiency leads to a condition called pernicious anemia,
• 23:49
  SPEAKER_00: which is characterized by massive, abnormally formed red blood cells.
• 23:53
  SPEAKER_01: But there are neurological consequences too, right?
• 23:56
  SPEAKER_00: Huge ones.
• 23:57
  SPEAKER_00: It leads to subacute combined degeneration of the spinal cord.
• 24:01
  SPEAKER_00: The myelin in the dorsal and lateral columns of the spinal cord literally demyelinates.
• 24:07
  SPEAKER_00: Patients lose their sense of position,
• 24:09
  SPEAKER_00: their gait becomes violently unsteady, and they develop severe spasticity.
• 24:14
  SPEAKER_00: It is devastating, and if left too long, irreversible.
• 24:18
  SPEAKER_01: But in an outpatient psychiatry clinic,
• 24:20
  SPEAKER_01: we usually aren't seeing people in the end stages of subacute combined degeneration.
• 24:26
  SPEAKER_01: We are looking at more subtle, disguised presentations.
• 24:30
  SPEAKER_01: Let's talk about the biomarkers,
• 24:31
  SPEAKER_01: because the sources point out a massive,
• 24:33
  SPEAKER_01: highly consequential trap here that clinicians fall into all the time.
• 24:38
  SPEAKER_01: The borderline trap.
• 24:40
  SPEAKER_00: Yes, this is a critical clinical pearl that must be internalized.
• 24:45
  SPEAKER_00: Standard laboratory reference ranges for CRM B12 usually set the lower limit
• 24:49
  SPEAKER_00: of normal around 200 to 250 picograms per milliliter, or PG slash ML.
• 24:54
  SPEAKER_00: Right.
• 24:55
  SPEAKER_00: If a patient's blood work comes back at 180,
• 24:58
  SPEAKER_00: the computer flies it in red as low, and every physician knows exactly what to do.
• 25:02
  SPEAKER_00: But what if a symptomatic patient comes back at 310 PG per ML?
• 25:07
  SPEAKER_01: The computer says normal.
• 25:08
  SPEAKER_01: The doctor looks at the sheet,
• 25:10
  SPEAKER_01: says your B12 is perfectly fine, and moves on to prescribing an antidepressant.
• 25:14
  SPEAKER_00: Exactly.
• 25:16
  SPEAKER_00: But the textbook and the underlying biochemistry says otherwise.
• 25:21
  SPEAKER_00: Serum B12 levels up to 400 pg per ml demand a much closer look,
• 25:26
  SPEAKER_00: especially if the patient is exhibiting neurological or psychiatric symptoms.
• 25:30
  SPEAKER_01: Because it might not be enough for that specific patient's brain.
• 25:34
  SPEAKER_00: Right.
• 25:35
  SPEAKER_00: In these borderline cases, simply measuring total serum B12 is fundamentally inadequate.
• 25:40
  SPEAKER_00: It isn't sensitive enough.
• 25:42
  SPEAKER_00: You need to order a secondary, highly specific metabolic test.
• 25:46
  SPEAKER_00: Okay,
• 25:49
  SPEAKER_01: why MMA?
• 25:50
  SPEAKER_01: What is the biochemical relationship there?
• 25:52
  SPEAKER_01: What does an MMA test tell us that the standard B12 test doesn't?
• 25:56
  SPEAKER_00: B12 acts as an essential enzymatic cofactor in a very specific metabolic pathway.
• 26:02
  SPEAKER_00: The conversion of methylmeloid CoA to succinyl CoA.
• 26:07
  SPEAKER_00: If you do not have enough functional active B12 inside the actual cells to drive
• 26:13
  SPEAKER_00: that enzyme,
• 26:14
  SPEAKER_00: even if there appears to be enough total B12 floating inertly in the bloodstream,
• 26:18
  SPEAKER_00: that pathway stalls out.
• 26:21
  SPEAKER_00: The biochemical assembly line halts.
• 26:24
  SPEAKER_00: And as a result,
• 26:25
  SPEAKER_00: the raw material,
• 26:26
  SPEAKER_00: methylmalonic acid, backs up and spills over into the blood and urine.
• 26:30
  SPEAKER_01: That is a brilliant mechanical explanation.
• 26:33
  SPEAKER_01: The standard serum B12 test is basically just counting the total number
• 26:36
  SPEAKER_01: of factory workers standing around outside the factory gates.
• 26:40
  SPEAKER_01: The MMA test tells you if those workers are actually inside the building,
• 26:44
  SPEAKER_01: on the assembly line, doing the work.
• 26:46
  SPEAKER_00: Spot on.
• 26:47
  SPEAKER_00: Therefore,
• 26:48
  SPEAKER_00: an elevated MMA level,
• 26:50
  SPEAKER_00: specifically greater than 0.271 micromoles per liter,
• 26:54
  SPEAKER_00: is a highly sensitive,
• 26:56
  SPEAKER_00: highly reliable indicator of a hidden functional B12 deficiency,
• 27:00
  SPEAKER_00: regardless of what the standard serum test says.
• 27:03
  SPEAKER_01: And if the workers aren't doing the work, the clinical manifestations can be devastating.
• 27:08
  SPEAKER_01: And crucially for this deep dive, they masquerade entirely as primary psychiatric illnesses.
• 27:13
  SPEAKER_01: It is a disguised deficiency.
• 27:15
  SPEAKER_00: What are the primary presenting symptoms you saw in the text?
• 27:18
  SPEAKER_01: According to the literature,
• 27:19
  SPEAKER_01: it's the insidious onset of depression,
• 27:22
  SPEAKER_01: profound unexplained irritability,
• 27:24
  SPEAKER_01: severe insomnia,
• 27:25
  SPEAKER_01: cognitive slowing that mimics early stage dementia
• 27:28
  SPEAKER_01: and even frank terrifying psychosis.
• 27:31
  SPEAKER_00: That's a broad spectrum.
• 27:33
  SPEAKER_01: Yeah.
• 27:34
  SPEAKER_01: Imagine a 68-year-old patient presenting to a clinic with increasing memory loss,
• 27:39
  SPEAKER_01: apathy, and depressive symptoms.
• 27:41
  SPEAKER_01: It is terribly easy to just diagnose them with geriatric depression
• 27:45
  SPEAKER_01: or mild cognitive impairment,
• 27:47
  SPEAKER_01: start them on an SSRI and a memory medication,
• 27:49
  SPEAKER_01: and completely miss the fact that their myelin is starving for cobalamin.
• 27:54
  SPEAKER_00: And we must urgently discuss the demographics because our sources indicate
• 27:57
  SPEAKER_00: a massive shift in who is actually at risk for this.
• 28:00
  SPEAKER_01: Yes, who is at risk?
• 28:02
  SPEAKER_01: Obviously,
• 28:02
  SPEAKER_01: older adults due to age-related decline in gastric acid,
• 28:06
  SPEAKER_01: but the epidemiology is changing.
• 28:08
  SPEAKER_00: It is shifting dramatically.
• 28:10
  SPEAKER_00: We historically thought of this mainly as an affliction of the elderly.
• 28:14
  SPEAKER_00: Estimates suggest up to 15% of older adults are clinically deficient.
• 28:18
  SPEAKER_00: But longitudinal data from the Framing How Offspring study revealed
• 28:22
  SPEAKER_00: that deficiency rates in younger adults,
• 28:24
  SPEAKER_00: aged 26 to 49, are now statistically similar to those over 65.
• 28:30
  SPEAKER_01: Why the demographic shift to younger populations?
• 28:32
  SPEAKER_01: What has changed in the last few decades?
• 28:35
  SPEAKER_00: A confluence of dietary, surgical, and pharmacological factors.
• 28:40
  SPEAKER_00: The rapid rise in strict vegan and vegetarian diets
• 28:43
  SPEAKER_00: without meticulous supplementation is a primary driver as B12 is absent
• 28:47
  SPEAKER_00: from plant sources.
• 28:49
  SPEAKER_01: Okay, diet is one.
• 28:51
  SPEAKER_01: What about surgical?
• 28:53
  SPEAKER_00: We also see an epidemic of malabsorption issues.
• 28:56
  SPEAKER_00: Patients
• 28:56
  SPEAKER_00: who have undergone bariatric surgery like gastric bypass have physically altered
• 29:01
  SPEAKER_00: the architecture of their stomach and intestines.
• 29:03
  SPEAKER_00: They are bypassing the exact sites where intrinsic factor binds to B12 for absorption.
• 29:09
  SPEAKER_00: Individuals with inflammatory bowel disease
• 29:12
  SPEAKER_00: or untreated celiac disease suffer similar malabsorption.
• 29:16
  SPEAKER_01: What about the pharmacological factors?
• 29:18
  SPEAKER_01: You mentioned medications interfering with vitamin D earlier.
• 29:21
  SPEAKER_01: Do common drugs block B12?
• 29:24
  SPEAKER_00: Massively.
• 29:25
  SPEAKER_00: And these are some of the most commonly prescribed drugs in the world.
• 29:29
  SPEAKER_00: Chronic,
• 29:30
  SPEAKER_00: long-term use of metformin,
• 29:32
  SPEAKER_00: the frontline treatment for type 2 diabetes,
• 29:34
  SPEAKER_00: significantly impairs the gut's ability to absorb B12.
• 29:38
  SPEAKER_01: Oh, wow.
• 29:39
  SPEAKER_01: Metformin.
• 29:40
  SPEAKER_00: Yes.
• 29:41
  SPEAKER_00: Similarly,
• 29:42
  SPEAKER_00: chronic use of proton pump inhibitors like omeprazole for acid reflux suppresses
• 29:46
  SPEAKER_00: the gastric acid necessary to cleave B12 away from dietary proteins,
• 29:51
  SPEAKER_00: rendering it unabsorbable.
• 29:52
  SPEAKER_01: So we have this absolutely vital nutrient,
• 29:55
  SPEAKER_01: a tricky testing landscape fraught with borderline traps,
• 29:58
  SPEAKER_01: and symptoms that look exactly like standard psychiatric disease driven
• 30:02
  SPEAKER_01: by common modern medications.
• 30:05
  SPEAKER_01: We must have massive,
• 30:07
  SPEAKER_01: robust RCTs testing isolated B12 as a primary psychiatric treatment, right?
• 30:12
  SPEAKER_00: Well, here is the great paradox of the B12 literature.
• 30:15
  SPEAKER_00: We actually don't.
• 30:16
  SPEAKER_01: We don't?
• 30:17
  SPEAKER_00: Almost no major high-quality RCTs
• 30:20
  SPEAKER_00: to date have tested isolated vitamin B12 supplementation as
• 30:23
  SPEAKER_00: a standalone intervention in primary psychiatric illness.
• 30:27
  SPEAKER_00: When it is tested in the literature,
• 30:29
  SPEAKER_00: it is almost always co-supplemented with folate or vitamin B6.
• 30:34
  SPEAKER_01: Why?
• 30:34
  SPEAKER_01: Why?
• 30:35
  SPEAKER_01: If the biology is so clear,
• 30:36
  SPEAKER_01: why haven't we isolated it in large psychiatric trials to prove efficacy?
• 30:41
  SPEAKER_00: Primarily because the B vitamins work synergistically,
• 30:43
  SPEAKER_00: tightly interlocked in the body,
• 30:45
  SPEAKER_00: particularly within the one carbon metabolism cycle, which we will dissect shortly.
• 30:49
  SPEAKER_00: From a research design perspective, it's hard to isolate one gear in a clockwork mechanism.
• 30:54
  SPEAKER_01: That makes research difficult.
• 30:56
  SPEAKER_00: It does.
• 30:57
  SPEAKER_00: But from an evidence-based medicine perspective,
• 30:59
  SPEAKER_00: this leaves the clinician in a very tricky spot.
• 31:02
  SPEAKER_00: Because we lack isolated,
• 31:03
  SPEAKER_00: high-quality RCT data,
• 31:05
  SPEAKER_00: we cannot formally recommend B12 as a standalone psychiatric treatment for someone
• 31:09
  SPEAKER_00: with entirely normal, healthy baseline levels.
• 31:12
  SPEAKER_01: But wait, let me push back on the clinical reality here.
• 31:15
  SPEAKER_01: If a patient is sitting across from me suffering from depression
• 31:18
  SPEAKER_01: and severe cognitive slowing and their serum B12 is 280 PGML
• 31:24
  SPEAKER_01: and their MMA is elevated,
• 31:27
  SPEAKER_01: are you saying I shouldn't treat the B12 because there isn't
• 31:29
  SPEAKER_01: a massive psychiatric RCT proving it cures depression?
• 31:33
  SPEAKER_00: Not at all.
• 31:34
  SPEAKER_00: This is exactly where conceptual synthesis and clinical reasoning step in.
• 31:39
  SPEAKER_00: B12 is a water-soluble vitamin.
• 31:41
  SPEAKER_00: Excess quantities are not stored to a toxic degree.
• 31:44
  SPEAKER_00: The body simply excretes what it cannot use.
• 31:46
  SPEAKER_01: So it's safe.
• 31:48
  SPEAKER_00: Very safe.
• 31:49
  SPEAKER_00: Therefore, supplementation poses a phenomenally low risk of toxicity.
• 31:53
  SPEAKER_00: So if a patient presents with symptoms consistent with deficiency
• 31:57
  SPEAKER_00: and their laboratory levels are deficient or caught in that borderline trap with
• 32:01
  SPEAKER_00: an elevated MMA, clinical reasoning dictates you must aggressively replace it.
• 32:07
  SPEAKER_01: Because you are treating the underlying biological deficit.
• 32:10
  SPEAKER_00: Exactly.
• 32:11
  SPEAKER_00: Which may completely resolve the masquerading psychiatric symptoms.
• 32:15
  SPEAKER_01: Okay, that makes perfect logical sense.
• 32:18
  SPEAKER_01: The safety profile is excellent,
• 32:20
  SPEAKER_01: and the potential upside is reversing a mimicking psychiatric illness.
• 32:24
  SPEAKER_01: But I have a very practical, patient-centric pushback.
• 32:28
  SPEAKER_01: Let's say my patient has a genuine deficiency due to pernicious anemia or metformin use.
• 32:35
  SPEAKER_01: They have an absorption issue.
• 32:37
  SPEAKER_01: Do I have to subject them to painful intramuscular B12 injections?
• 32:41
  SPEAKER_01: Because historically, that is what I always see happening in clinics.
• 32:44
  SPEAKER_01: Big, red, highly painful shots into the deltoid or glute.
• 32:48
  SPEAKER_00: That has been the traditional dogma for decades,
• 32:50
  SPEAKER_00: especially for pernicious anemia or severe malabsorption.
• 32:55
  SPEAKER_00: But the evidence base has evolved significantly.
• 32:58
  SPEAKER_00: A landmark 2018 Cochran Review looked specifically at this root of administration question.
• 33:04
  SPEAKER_01: And what did they find?
• 33:05
  SPEAKER_00: They found clear,
• 33:06
  SPEAKER_00: compelling evidence that daily oral supplementation using very high doses of 1,000
• 33:12
  SPEAKER_00: to 2,000 micrograms is just as efficacious,
• 33:15
  SPEAKER_00: just as safe,
• 33:16
  SPEAKER_00: and significantly more cost effective than intramuscular injections
• 33:20
  SPEAKER_00: for normalizing serum levels and treating the deficiency.
• 33:24
  SPEAKER_01: I need you to explain the mechanics of that.
• 33:26
  SPEAKER_01: If the patient has pernicious anemia,
• 33:29
  SPEAKER_01: Meaning they literally lack the intrinsic factor required to actively absorb B12 in
• 33:33
  SPEAKER_01: the gut.
• 33:35
  SPEAKER_01: How does swallowing a pill work?
• 33:37
  SPEAKER_01: It should just pass straight through them.
• 33:39
  SPEAKER_00: It's all about brute force and passive diffusion.
• 33:43
  SPEAKER_00: The gut has two ways of absorbing B12.
• 33:45
  SPEAKER_00: The highly efficient active transport mechanism requires intrinsic factor.
• 33:50
  SPEAKER_00: That's the mechanism that is broken in pernicious anemia or gastric bypass.
• 33:54
  SPEAKER_01: Right.
• 33:55
  SPEAKER_00: But there is a secondary mechanism, passive diffusion across the mucosal barrier.
• 34:00
  SPEAKER_00: It is incredibly inefficient.
• 34:02
  SPEAKER_00: Only about 1% of the B12 presented to the gut wall is absorbed this way.
• 34:06
  SPEAKER_01: Ah, I see the math here.
• 34:08
  SPEAKER_00: Right.
• 34:08
  SPEAKER_00: If you eat a steak containing 3 micrograms of B12, 1% of that is useless.
• 34:13
  SPEAKER_00: But if you flood the gastrointestinal system with a massive oral dose
• 34:17
  SPEAKER_00: of 2,000 micrograms daily, 1% of that is 20 micrograms.
• 34:21
  SPEAKER_01: And what's the daily requirement?
• 34:23
  SPEAKER_00: The daily requirement for an adult is only about 2.4 micrograms.
• 34:27
  SPEAKER_01: Oh, wow.
• 34:28
  SPEAKER_00: So by using high-dose oral therapy,
• 34:31
  SPEAKER_00: you brute force enough B12 across the barrier via passive diffusion
• 34:35
  SPEAKER_00: to easily meet daily requirements and eventually replete the hepatic stores,
• 34:40
  SPEAKER_00: entirely bypassing the broken active transport system.
• 34:43
  SPEAKER_00: No needles required.
• 34:45
  SPEAKER_01: That is a fantastic clinical pearl.
• 34:47
  SPEAKER_01: It spares the patient pain, saves clinical time, and reduces healthcare costs.
• 34:53
  SPEAKER_01: So, the core synthesis for B12,
• 34:55
  SPEAKER_01: beware the borderline trap,
• 34:57
  SPEAKER_01: utilize the MMA test,
• 34:59
  SPEAKER_01: recognize the masquerading psychiatric symptoms,
• 35:02
  SPEAKER_01: and confidently use high-dose oral replacement.
• 35:05
  SPEAKER_00: Exactly.
• 35:06
  SPEAKER_00: We aren't prescribing it as a novel antidepressant.
• 35:10
  SPEAKER_00: We are diligently removing a biological barrier to neurological health.
• 35:15
  SPEAKER_01: Let's move deeper into the biochemistry.
• 35:17
  SPEAKER_01: We've mentioned it several times, so we must confront it.
• 35:20
  SPEAKER_01: Let's examine folate or vitamin B9 and the infamous methylation cycle.
• 35:25
  SPEAKER_01: I find this to be the most complex mechanism in the entire chapter.
• 35:28
  SPEAKER_01: It is a dizzying array of metabolic pathways.
• 35:32
  SPEAKER_01: Neurotransmitter synthesis, CNS phospholipid synthesis, homocysteine metabolism.
• 35:38
  SPEAKER_01: How do we conceptualize folate's role in all of this?
• 35:40
  SPEAKER_00: It is incredibly complex, but we can simplify the mental model.
• 35:45
  SPEAKER_00: Folate is an enzymatic cofactor.
• 35:48
  SPEAKER_00: Think of it as the great facilitator in the brain.
• 35:50
  SPEAKER_00: It doesn't actually form the physical structures itself.
• 35:53
  SPEAKER_00: It enables the specific enzymes that do the crucial work.
• 35:57
  SPEAKER_01: Okay.
• 35:57
  SPEAKER_01: The facilitator.
• 35:59
  SPEAKER_00: Specifically,
• 36:00
  SPEAKER_00: it drives the one carbon metabolism cycle,
• 36:03
  SPEAKER_00: which is universally referred to as the methylation cycle.
• 36:06
  SPEAKER_01: Break down methylation for us.
• 36:08
  SPEAKER_01: What is actually happening at a cellular level?
• 36:11
  SPEAKER_00: Think of methylation as the body's method of passing a microscopic chemical baton,
• 36:15
  SPEAKER_00: specifically a single methyl group,
• 36:17
  SPEAKER_00: which is just one carbon atom attached to three hydrogen atoms.
• 36:21
  SPEAKER_01: Okay.
• 36:22
  SPEAKER_00: The body passes this baton from one molecule to another to activate or deactivate them.
• 36:28
  SPEAKER_00: This relentless baton passing is biologically mandatory
• 36:31
  SPEAKER_00: to manufacture monoamine neurotransmitters like serotonin,
• 36:35
  SPEAKER_00: dopamine, and norepinephrine.
• 36:37
  SPEAKER_00: It is required to build the complex phospholipids that make up the cell membranes
• 36:40
  SPEAKER_00: of our neurons.
• 36:42
  SPEAKER_00: And crucially, it is required to break down and recycle homocysteine.
• 36:46
  SPEAKER_01: What happens if homocysteine isn't broken down?
• 36:49
  SPEAKER_00: Homocysteine is a toxic inflammatory amino acid.
• 36:54
  SPEAKER_00: If the methylation cycle stalls due to a lack of folate, homocysteine accumulates in the blood.
• 37:00
  SPEAKER_00: High levels of homocysteine are directly toxic to the vascular endothelium,
• 37:04
  SPEAKER_00: the lining of the blood vessels,
• 37:06
  SPEAKER_00: leading to microvascular damage in the brain,
• 37:08
  SPEAKER_00: which is strongly linked to depression and vascular dementia.
• 37:12
  SPEAKER_01: So without folate,
• 37:13
  SPEAKER_01: the chemical baton gets dropped,
• 37:15
  SPEAKER_01: the neurotransmitters don't get manufactured,
• 37:17
  SPEAKER_01: the neuronal cell walls become weak, and vascular toxins build up.
• 37:21
  SPEAKER_01: It's a systemic biological failure.
• 37:23
  SPEAKER_00: Precisely.
• 37:24
  SPEAKER_00: And this is where we run into a fascinating public health phenomenon
• 37:29
  SPEAKER_00: that we can call the fortification paradox.
• 37:31
  SPEAKER_01: What is the
• 37:32
  SPEAKER_00: paradox?
• 37:32
  SPEAKER_00: Well, in 1998,
• 37:35
  SPEAKER_00: in a landmark move to prevent neural tube defects like spina bifida
• 37:38
  SPEAKER_00: in developing fetuses,
• 37:40
  SPEAKER_00: the FDA mandated that all enriched grain products in the United States,
• 37:44
  SPEAKER_00: breads, cereals, pastas, be fortified with synthetic folic acid.
• 37:49
  SPEAKER_01: Right.
• 37:49
  SPEAKER_01: I remember that.
• 37:50
  SPEAKER_00: It was a massive, unequivocal public health triumph.
• 37:53
  SPEAKER_00: Because of this sweeping mandate,
• 37:55
  SPEAKER_00: true profound folate deficiency,
• 37:57
  SPEAKER_00: which is clinically defined as a serum level of less
• 38:00
  SPEAKER_00: than three nanograms per milliliter, is incredibly rare today.
• 38:05
  SPEAKER_00: A massive epidemiological study in Boston found true deficiency in only 0.06% of
• 38:11
  SPEAKER_00: the individuals they tested.
• 38:13
  SPEAKER_01: Oh, wait, I have to stop you there.
• 38:14
  SPEAKER_01: If the FDA mandated folic acid fortification nearly three decades ago,
• 38:18
  SPEAKER_01: and true deficiency is essentially eradicated at 0.06%,
• 38:23
  SPEAKER_01: Then why are we even discussing this as a psychiatric intervention?
• 38:26
  SPEAKER_01: The problem is solved.
• 38:27
  SPEAKER_00: True deficiency is eradicated, but insufficiency is decidedly not.
• 38:32
  SPEAKER_00: Recent National Health and Nutrition Examination Survey,
• 38:35
  SPEAKER_00: or NHANES data,
• 38:37
  SPEAKER_00: reveals that folate insufficiency,
• 38:39
  SPEAKER_00: defined as serum levels below 7 nanograms per milliliter,
• 38:43
  SPEAKER_00: still hovers around 20% in the general U.S. population.
• 38:48
  SPEAKER_01: One in five people are walking around with suboptimal levels,
• 38:51
  SPEAKER_01: despite the grain supply being fortified.
• 38:53
  SPEAKER_01: How is the math on that possible unless there is an absorption or conversion issue?
• 38:57
  SPEAKER_00: That is exactly the issue.
• 38:59
  SPEAKER_00: The insufficiency is driven partially by terrible diets lacking leafy greens,
• 39:04
  SPEAKER_00: excessive alcohol intake, which impairs absorption, and malabsorption syndromes.
• 39:08
  SPEAKER_00: But the critical driving factor is a widespread genetic variant, the MTHFR gene mutation.
• 39:16
  SPEAKER_01: Okay, we must unpack MTHFR.
• 39:19
  SPEAKER_01: It has become a massive buzzword on the wellness internet.
• 39:22
  SPEAKER_01: What is the actual unexaggerated biology of what this gene does?
• 39:26
  SPEAKER_00: MTHFR stands for methylene tetrahydrofolate reductase.
• 39:31
  SPEAKER_00: It is the crucial enzyme responsible for converting
• 39:33
  SPEAKER_00: the inactive synthetic folic acid we eat in our fortified bread.
• 39:38
  SPEAKER_00: Into L-methylfolate,
• 39:39
  SPEAKER_00: which is the active,
• 39:41
  SPEAKER_00: biologically available form that can actually cross the blood-brain barrier
• 39:45
  SPEAKER_00: and facilitate the methylation cycle we just discussed.
• 39:48
  SPEAKER_01: So it's the gatekeeper enzyme.
• 39:50
  SPEAKER_00: Exactly.
• 39:52
  SPEAKER_00: But a significant portion of the global population inherits genetic variants
• 39:55
  SPEAKER_00: of this gene, specifically the C677T polymorphism.
• 40:00
  SPEAKER_00: These variants cause the resulting MTHFR enzyme to fold slightly incorrectly,
• 40:05
  SPEAKER_00: making it incredibly sluggish and inefficient at its job.
• 40:08
  SPEAKER_01: So it doesn't work as well.
• 40:10
  SPEAKER_00: Right.
• 40:11
  SPEAKER_00: People with this variant can eat plenty of fortified grains.
• 40:14
  SPEAKER_00: Their blood might even show adequate levels of inactive folic acid.
• 40:18
  SPEAKER_00: But their brain remains starved of the active L-methylfolate because
• 40:22
  SPEAKER_00: the conversion process is bottlenecked.
• 40:24
  SPEAKER_01: Ah.
• 40:25
  SPEAKER_01: So the factory warehouse is completely full of raw materials,
• 40:27
  SPEAKER_01: but the specific machine that processes them into a usable product is broken.
• 40:32
  SPEAKER_01: So no finished product ever gets to the assembly line?
• 40:35
  SPEAKER_00: That is a perfect encapsulation.
• 40:38
  SPEAKER_00: And low levels of active folate in the brain have been strongly
• 40:41
  SPEAKER_00: and consistently associated with major depressive disorder,
• 40:44
  SPEAKER_00: early onset dementia, and schizophrenia.
• 40:47
  SPEAKER_01: So what happens when we bypass the broken machine and use active folate as
• 40:51
  SPEAKER_01: a targeted psychiatric treatment?
• 40:53
  SPEAKER_01: Let's look at the RCT data, starting with depression.
• 40:56
  SPEAKER_00: We have a highly robust meta-analysis of nine RCTs involving 1,061 adult patients
• 41:03
  SPEAKER_00: with major depressive disorder.
• 41:05
  SPEAKER_00: They investigated using folate,
• 41:07
  SPEAKER_00: Either standard folic acid or the active L-methylfolate as
• 41:11
  SPEAKER_00: an adjunctive treatment added to their standard antidepressant therapy.
• 41:16
  SPEAKER_01: And what were the results on the symptom scales?
• 41:18
  SPEAKER_00: The overall effect size on broad symptom reduction was small.
• 41:22
  SPEAKER_00: It yielded an SMD of minus 0.38.
• 41:25
  SPEAKER_01: So using our analogy, that's just a desk lamp.
• 41:28
  SPEAKER_01: It helps a bit, but it isn't revolutionary.
• 41:31
  SPEAKER_00: If you only look at the SMD, yes.
• 41:33
  SPEAKER_00: However, this is why clinical reasoning must go deeper than the top-line summary.
• 41:39
  SPEAKER_00: We need to look at a fundamentally different metric reported in that data,
• 41:43
  SPEAKER_00: the number needed to treat, or NNT, for achieving full remission.
• 41:48
  SPEAKER_01: Break down the concept of NNT for the listener and clarify the difference
• 41:51
  SPEAKER_01: between symptom reduction and true remission.
• 41:54
  SPEAKER_00: NNT is a statistical concept that tells you how many total patients you need
• 42:00
  SPEAKER_00: to treat with the active intervention
• 42:02
  SPEAKER_00: to achieve exactly one additional positive outcome compared to the placebo group.
• 42:06
  SPEAKER_01: So lower is better.
• 42:08
  SPEAKER_00: A lower number is vastly better.
• 42:11
  SPEAKER_00: An NNT of five means you treat five people and one of them gets
• 42:15
  SPEAKER_00: a benefit they wouldn't have otherwise had.
• 42:17
  SPEAKER_00: And remission doesn't just mean they feel slightly less sad.
• 42:21
  SPEAKER_00: It means their symptom scores have dropped so low
• 42:24
  SPEAKER_00: that they essentially no longer meet the clinical criteria for depression.
• 42:27
  SPEAKER_00: They are effectively well.
• 42:29
  SPEAKER_01: And what was the NNT for folate inducing that state of wellness?
• 42:34
  SPEAKER_00: In this meta-analysis, the NNT for inducing remission was an astounding 0.8.
• 42:39
  SPEAKER_01: Wow.
• 42:40
  SPEAKER_01: So for every 0.8 depressed patients given folate alongside their standard SSRI,
• 42:46
  SPEAKER_01: one achieved full complete remission who otherwise would have remained depressed on
• 42:50
  SPEAKER_01: the medication alone.
• 42:51
  SPEAKER_00: Yes.
• 42:52
  SPEAKER_00: Looking at the raw percentages,
• 42:54
  SPEAKER_00: 48% of the patients in the folate group achieved full remission,
• 42:58
  SPEAKER_00: compared to only 27% on the placebo.
• 43:01
  SPEAKER_00: That is a massive, life-altering clinical difference.
• 43:05
  SPEAKER_01: That's not just a desk lamp.
• 43:06
  SPEAKER_01: That's turning on the overhead lights for nearly half the patients in the room.
• 43:10
  SPEAKER_01: Who did this intervention work best for?
• 43:13
  SPEAKER_01: Did they do a subgroup analysis?
• 43:15
  SPEAKER_00: They did.
• 43:15
  SPEAKER_00: The subgroup analyses revealed it worked best in trials lasting less than 15 weeks,
• 43:20
  SPEAKER_00: suggesting the biological benefit plateaus.
• 43:22
  SPEAKER_00: And critically,
• 43:23
  SPEAKER_00: it worked significantly better in younger participants,
• 43:26
  SPEAKER_00: specifically those under 42 years old.
• 43:29
  SPEAKER_01: Why younger patients?
• 43:30
  SPEAKER_00: There is strong physiological suggestion that as we age,
• 43:34
  SPEAKER_00: our capacity for folate absorption and one-carbon metabolism alters.
• 43:38
  SPEAKER_00: Or perhaps chronic decades-long illness changes the neurobiological dynamics in
• 43:44
  SPEAKER_00: a way folate can no longer easily reverse.
• 43:47
  SPEAKER_01: So for a 35-year-old patient on an SSRI who has seen some improvement
• 43:52
  SPEAKER_01: but just isn't quite getting across the finish line to remission,
• 43:55
  SPEAKER_01: adding active folate seems like an incredibly smart,
• 43:58
  SPEAKER_01: low-risk, evidence-based augmentation strategy.
• 44:01
  SPEAKER_01: You mentioned schizophrenia earlier.
• 44:03
  SPEAKER_01: Does the baton pass matter there?
• 44:05
  SPEAKER_00: Yes, and this is where we truly enter the realm of precision psychiatric medicine.
• 44:09
  SPEAKER_00: If you look at a broad,
• 44:10
  SPEAKER_00: unstratified meta-analysis of four RCTs in schizophrenia,
• 44:15
  SPEAKER_00: it showed that overall folate supplementation was not superior to placebo.
• 44:19
  SPEAKER_01: So a statistical dead end for schizophrenia.
• 44:22
  SPEAKER_00: But a diligent clinician never stops at the top-line summary of a failed trial.
• 44:26
  SPEAKER_00: When you dissect the individual trials that utilized precision biomarker targeting,
• 44:32
  SPEAKER_00: a radically different narrative emerges.
• 44:33
  SPEAKER_01: Oh, really?
• 44:34
  SPEAKER_00: The researchers found that patients who possessed specific genetic variants,
• 44:39
  SPEAKER_00: specifically variants in the MTR gene,
• 44:41
  SPEAKER_00: which works closely with MTHFR in the methylation cycle,
• 44:45
  SPEAKER_00: or patients who possessed documented low baseline folate levels,
• 44:49
  SPEAKER_00: showed remarkable transformative improvements when they were given 15 milligrams of
• 44:54
  SPEAKER_00: the active L-methylfolate.
• 44:56
  SPEAKER_01: How remarkable are we talking?
• 44:58
  SPEAKER_01: What were the effect sizes?
• 44:59
  SPEAKER_00: Moderate to large effect sizes.
• 45:01
  SPEAKER_00: We saw SMDs ranging from 0.63 to 0.84,
• 45:06
  SPEAKER_00: specifically for improving negative symptoms and general psychopathology.
• 45:11
  SPEAKER_00: One trial even demonstrated beneficial structural changes in MRI measures,
• 45:16
  SPEAKER_00: showcasing improved resting connectivity and increased cortical thickness
• 45:20
  SPEAKER_00: in specific brain regions.
• 45:21
  SPEAKER_01: That is wild.
• 45:23
  SPEAKER_01: For context,
• 45:24
  SPEAKER_01: negative symptoms in schizophrenia—the profound apathy,
• 45:27
  SPEAKER_01: the flattening of affect,
• 45:28
  SPEAKER_01: the poverty of speech,
• 45:30
  SPEAKER_01: the social withdrawal—are notoriously, notoriously difficult to treat.
• 45:35
  SPEAKER_01: Standard antipsychotic medications primarily target the positive symptoms,
• 45:39
  SPEAKER_01: like hallucinations, but they barely touch the negative symptoms.
• 45:43
  SPEAKER_01: If targeted L-methylfolate can move the needle on negative symptoms with an SMD
• 45:48
  SPEAKER_01: of 0.84, that is a paradigm-shifting tool.
• 45:51
  SPEAKER_00: It is a profound tool,
• 45:53
  SPEAKER_00: but it is vital to remember the caveat,
• 45:56
  SPEAKER_00: it only works for the right patient,
• 45:59
  SPEAKER_00: the one with the specific biological vulnerability and
• 46:02
  SPEAKER_00: the compromised methylation cycle.
• 46:04
  SPEAKER_01: Okay, here is where I must interject with a massive warning bell.
• 46:10
  SPEAKER_01: We've established that folate is powerful.
• 46:12
  SPEAKER_01: It can induce remission in stubborn depression
• 46:14
  SPEAKER_01: and dramatically improve untreatable negative symptoms in targeted schizophrenia.
• 46:19
  SPEAKER_01: So, Human nature dictates if some is good, more is better.
• 46:24
  SPEAKER_01: Why not just give high dose active folate to absolutely everyone who walks into
• 46:28
  SPEAKER_01: a psychiatric clinic?
• 46:29
  SPEAKER_01: What is the danger zone regarding folate?
• 46:34
  SPEAKER_00: The danger zone is very real and it is a matter of strict medical safety.
• 46:39
  SPEAKER_00: Unlike vitamin B12,
• 46:41
  SPEAKER_00: the Food and Nutrition Board has established a hard, strict,
• 46:45
  SPEAKER_00: upper tolerable intake limit for supplemental inactive folic acid
• 46:50
  SPEAKER_00: of one gram per day for adults.
• 46:52
  SPEAKER_01: Why?
• 46:53
  SPEAKER_01: What is the physiological consequence of exceeding that one gram limit?
• 46:57
  SPEAKER_00: Firstly, high dose folic acid can dangerously and silently mask a severe B12 deficiency.
• 47:04
  SPEAKER_01: How does it do that?
• 47:05
  SPEAKER_01: Explain the mechanism of the masking.
• 47:08
  SPEAKER_00: The primary highly visible sign of a B12 deficiency
• 47:11
  SPEAKER_00: on standard blood work is macrocytic anemia.
• 47:14
  SPEAKER_00: The red blood cells become massively enlarged.
• 47:17
  SPEAKER_00: Folic acid and B12 work together to make red blood cells.
• 47:21
  SPEAKER_00: Right.
• 47:22
  SPEAKER_00: If you flood the body with high doses of folic acid,
• 47:25
  SPEAKER_00: it can forcibly correct the macrocytic anemia,
• 47:27
  SPEAKER_00: making the complete blood count look entirely normal.
• 47:31
  SPEAKER_00: But the folic acid does absolutely nothing to protect or repair the myelin sheath in
• 47:36
  SPEAKER_00: the nervous system.
• 47:38
  SPEAKER_00: So it corrects the blood,
• 47:40
  SPEAKER_00: blinding the physician to the problem while allowing
• 47:42
  SPEAKER_00: the silent irreversible neurological damage of the B12 deficiency
• 47:46
  SPEAKER_00: to continue progressing unchecked in the background.
• 47:49
  SPEAKER_01: Oh, wow.
• 47:50
  SPEAKER_00: It effectively puts out the smoke alarm while the fire keeps burning down the house.
• 47:55
  SPEAKER_01: Exactly.
• 47:56
  SPEAKER_00: Secondly,
• 47:57
  SPEAKER_00: very high doses of synthetic folic acid have been associated in some literature with
• 48:01
  SPEAKER_00: an acceleration of pre-neoplastic lesions,
• 48:04
  SPEAKER_00: essentially potentially providing the growth materials
• 48:07
  SPEAKER_00: that speed up certain early-stage cancers, particularly colorectal adenomas.
• 48:13
  SPEAKER_00: Thirdly,
• 48:14
  SPEAKER_00: extremely high maternal intake during pregnancy has been linked
• 48:16
  SPEAKER_00: in longitudinal cohorts to lower cognitive scores in children down the line.
• 48:22
  SPEAKER_01: Okay, so we strictly respect the one gram upper limit for standard synthetic folic acid.
• 48:27
  SPEAKER_01: But what about the active form, the 15 milligrams of L-methylfolate?
• 48:31
  SPEAKER_01: That seems to be the psychiatric powerhouse dose used in the successful trials.
• 48:35
  SPEAKER_01: Are there dangers with the active form?
• 48:38
  SPEAKER_00: Yes, there are distinct psychiatric risks.
• 48:40
  SPEAKER_00: There are multiple clinical case reports indicating that dropping 15 milligrams
• 48:44
  SPEAKER_00: of active L-methylfolate into a vulnerable system can trigger severe,
• 48:51
  SPEAKER_00: uncharacteristic irritability,
• 48:53
  SPEAKER_00: intense psychomotor agitation, and even precipitate full manic episodes.
• 48:57
  SPEAKER_01: Mania.
• 48:58
  SPEAKER_00: Yes, particularly in patients with underlying pain.
• 49:04
  SPEAKER_01: It's almost as if you are revving the engine of neurotransmitter synthesis too hard
• 49:10
  SPEAKER_01: and too fast.
• 49:11
  SPEAKER_00: That is the exact biological mechanism.
• 49:14
  SPEAKER_00: You are rapidly flooding the presynaptic neurons with the raw capacity
• 49:19
  SPEAKER_00: to manufacture massive amounts of dopamine and norepinephrine.
• 49:23
  SPEAKER_00: Right.
• 49:24
  SPEAKER_00: Right.
• 49:24
  SPEAKER_00: Right.
• 49:42
  SPEAKER_00: Limit the trial to no longer than 15 weeks since
• 49:46
  SPEAKER_00: the meta-analyses showed no additional benefit was gained after that point.
• 49:50
  SPEAKER_00: And monitor them like a hawk for signs of agitation or hypomania.
• 49:55
  SPEAKER_01: This investigation into folate is intense.
• 49:58
  SPEAKER_00: It is.
• 49:59
  SPEAKER_01: It offers incredibly powerful benefits,
• 50:00
  SPEAKER_01: but you absolutely have to drive the clinical car carefully.
• 50:03
  SPEAKER_00: Yeah, no question.
• 50:05
  SPEAKER_01: All right, let's step into the final major domain of our deep dive.
• 50:08
  SPEAKER_01: We are moving from the enzymatic facilitators to the actual structural ledger of the brain.
• 50:13
  SPEAKER_01: Let's examine omega-3 fatty acids.
• 50:16
  SPEAKER_00: Omega-3s.
• 50:17
  SPEAKER_00: These are polyunsaturated essential fatty acids.
• 50:21
  SPEAKER_00: The key word there is essential,
• 50:23
  SPEAKER_00: meaning like the vitamins we discussed,
• 50:25
  SPEAKER_00: our bodies lack the specific desaturated enzymes required to manufacture them
• 50:29
  SPEAKER_00: from scratch.
• 50:30
  SPEAKER_00: They must be consumed in the diet,
• 50:32
  SPEAKER_00: primarily from marine sources like fatty fish or certain algae.
• 50:36
  SPEAKER_01: And what are the main ones?
• 50:37
  SPEAKER_00: The two most prominent and neurologically significant omega-3s are DHA and EPA.
• 50:43
  SPEAKER_01: Looking at the literature,
• 50:44
  SPEAKER_01: DHA and EPA seem to have entirely different biological job descriptions.
• 50:50
  SPEAKER_01: How do they differ mechanically in the brain?
• 50:53
  SPEAKER_00: They are profoundly different.
• 50:55
  SPEAKER_00: Let's start with DHA, docohexanoic acid.
• 50:59
  SPEAKER_00: DHA is fundamentally structural.
• 51:01
  SPEAKER_00: It is so concentrated in the brain that it accounts for a staggering 40% of
• 51:06
  SPEAKER_00: the total polyunsaturated fatty acids in neuronal cell membranes.
• 51:10
  SPEAKER_01: 40%.
• 51:10
  SPEAKER_00: Yes.
• 51:11
  SPEAKER_00: Its physical shape creates spaces in the lipid bilayer, maintaining optimal membrane fluidity.
• 51:17
  SPEAKER_00: This fluidity is non-negotiable.
• 51:19
  SPEAKER_00: It helps neurotransmitter receptors embed correctly,
• 51:22
  SPEAKER_00: allows ion channels to open and close smoothly,
• 51:25
  SPEAKER_00: and aids in rapid signal transduction.
• 51:27
  SPEAKER_01: So DHA is the physical architecture.
• 51:31
  SPEAKER_00: It's the high-quality, flexible bricks and mortar of the brain.
• 51:34
  SPEAKER_01: Yes.
• 51:35
  SPEAKER_00: EPA, on the other hand, icosapentaenoic acid, is far more functional and dynamic.
• 51:42
  SPEAKER_00: It doesn't hang around statically in the cell membrane nearly as much as DHA.
• 51:46
  SPEAKER_00: Instead,
• 51:47
  SPEAKER_00: it acts as a highly potent anti-inflammatory and antioxidant agent within
• 51:51
  SPEAKER_00: the central nervous system.
• 51:53
  SPEAKER_01: How does it do that?
• 51:55
  SPEAKER_00: It directly competes with arachidonic acid to reduce the production
• 51:58
  SPEAKER_00: of pro-inflammatory cytokines and prostaglandins.
• 52:02
  SPEAKER_01: So if DHA builds the flexible house,
• 52:05
  SPEAKER_01: EPA is the chemical fire extinguisher rowing the halls
• 52:08
  SPEAKER_01: to calm down neuroinflammation.
• 52:11
  SPEAKER_01: Do we test for these lipid levels in the clinic like we do for vitamin D and B12?
• 52:16
  SPEAKER_00: We can perform red blood cell membrane fatty acid profiling
• 52:19
  SPEAKER_00: in specialized research settings, but broadly speaking, no.
• 52:24
  SPEAKER_00: There are currently no universally established standardized laboratory cutoffs
• 52:28
  SPEAKER_00: for omega-3 deficiency in routine clinical psychiatric practice.
• 52:32
  SPEAKER_00: Instead of targeting a specific blood level,
• 52:35
  SPEAKER_00: we rely entirely on adequate intake or AI guidelines,
• 52:39
  SPEAKER_00: which generally suggest consuming about 1.1 to 1.6 grams of total omega-3s per day
• 52:44
  SPEAKER_00: in adulthood.
• 52:46
  SPEAKER_01: Omega-3s have to be the most hyped and studied supplements in the history of the world.
• 52:51
  SPEAKER_01: I feel like every magazine,
• 52:52
  SPEAKER_01: podcast, and wellness guru tells me to eat salmon or take fish oil for my brain.
• 52:56
  SPEAKER_01: What do the rigorous psychiatric RCTs actually say when we strip away the marketing?
• 53:01
  SPEAKER_01: Let's start with major depressive disorder.
• 53:04
  SPEAKER_00: The data pool is massive.
• 53:06
  SPEAKER_00: We have a highly powered meta-analysis of 26 RCTs,
• 53:10
  SPEAKER_00: encompassing over 2,160 adults with clinical major depressive disorder.
• 53:16
  SPEAKER_00: And if you look at the top line result,
• 53:18
  SPEAKER_00: averaging all the different types of omega-3 supplements used
• 53:21
  SPEAKER_00: across all those trials,
• 53:23
  SPEAKER_00: the overall effect size
• 53:24
  SPEAKER_00: for reducing depressive symptoms was statistically significant, but small.
• 53:30
  SPEAKER_00: An SMD of negative 0.28.
• 53:33
  SPEAKER_01: Negative 0.28, so barely a desk lamp.
• 53:36
  SPEAKER_01: If that was the end of the story, fish oil wouldn't be worth the money.
• 53:39
  SPEAKER_00: Right.
• 53:40
  SPEAKER_00: But here is the key insight,
• 53:42
  SPEAKER_00: the absolute crux of understanding lipid supplementation in psychiatry.
• 53:46
  SPEAKER_00: Formulation matters immensely.
• 53:49
  SPEAKER_00: When the researchers stratified and broke the data down by the specific ratio of EPA
• 53:54
  SPEAKER_00: to DHA in the pills, the entire picture changed radically.
• 53:58
  SPEAKER_01: The ratio of the fire extinguisher to the structural bricks.
• 54:01
  SPEAKER_01: What happened?
• 54:02
  SPEAKER_00: Formulations that were EPA pure,
• 54:04
  SPEAKER_00: meaning the pill contained 100% EPA with zero DHA,
• 54:08
  SPEAKER_00: dosed up to one gram a day, gave a solid, moderate effect size of 0.50.
• 54:15
  SPEAKER_01: Okay, the light is getting brighter.
• 54:17
  SPEAKER_00: But the breakthrough came with formulations that were EPA major,
• 54:20
  SPEAKER_00: meaning the pill contained a mix,
• 54:23
  SPEAKER_00: but it was 60% or more EPA, dosed up to one gram a day.
• 54:27
  SPEAKER_00: That specific ratio yielded a large effect size, an SMD of negative 1.03.
• 54:34
  SPEAKER_01: Minus 1.03.
• 54:35
  SPEAKER_01: That is huge.
• 54:37
  SPEAKER_01: That is vaulting over the efficacy of standard SSRIs and approaching the efficacy
• 54:41
  SPEAKER_01: of advanced treatments like Transcranial magnetic stimulation.
• 54:45
  SPEAKER_01: Why is that specific ratio so powerful?
• 54:48
  SPEAKER_00: It is remarkably significant.
• 54:50
  SPEAKER_00: It tells us fundamentally about the underlying pathology of depression.
• 54:53
  SPEAKER_00: It strongly suggests that for many depressed patients,
• 54:57
  SPEAKER_00: the mood disorder is heavily driven by neuroinflammatory cascades.
• 55:01
  SPEAKER_01: So they need the fire extinguisher.
• 55:03
  SPEAKER_00: Exactly.
• 55:04
  SPEAKER_00: Therefore,
• 55:05
  SPEAKER_00: the potent anti-inflammatory action of the EPA is the primary mechanism
• 55:09
  SPEAKER_00: of action required.
• 55:10
  SPEAKER_00: But because the pure EPA,
• 55:12
  SPEAKER_00: which had an SMD of 0.50,
• 55:15
  SPEAKER_00: wasn't as effective as the EPA major blend at 1.03,
• 55:18
  SPEAKER_00: it implies that the EPA fire extinguisher works best when it is supported by
• 55:23
  SPEAKER_00: a smaller amount of the structural DHA bricks to simultaneously repair
• 55:27
  SPEAKER_00: the cellular damage the inflammation caused.
• 55:30
  SPEAKER_01: That is a profound, actionable clinical pearl.
• 55:33
  SPEAKER_01: A patient cannot just go to the local pharmacy Buy the cheapest massive jug
• 55:37
  SPEAKER_01: of generic fish oil off the bottom shelf and expect it to cure their depression.
• 55:41
  SPEAKER_01: They have to physically turn the bottle around,
• 55:43
  SPEAKER_01: read the nutritional ledger,
• 55:45
  SPEAKER_01: calculate the ratio of EPA to DHA and ensure they are buying
• 55:49
  SPEAKER_01: an EPA major formulation.
• 55:51
  SPEAKER_00: Precisely.
• 55:52
  SPEAKER_00: The vast majority of cheap commercial fish oils are heavily weighted towards DHA
• 55:56
  SPEAKER_00: because it is cheaper to extract.
• 55:58
  SPEAKER_00: If the ratio is inverted, it's mostly DHA.
• 56:01
  SPEAKER_00: The clinical data suggests it likely will not move the needle
• 56:04
  SPEAKER_00: on their depressive symptoms at all.
• 56:06
  SPEAKER_01: That is brilliant.
• 56:07
  SPEAKER_01: What about anxiety disorders?
• 56:10
  SPEAKER_01: Does the same EPA major rule apply across the board?
• 56:14
  SPEAKER_00: No, and this brings us to a fascinating biological paradox.
• 56:18
  SPEAKER_00: For anxiety, we examined a meta-analysis of 19 RCTs involving 2,240 adults.
• 56:25
  SPEAKER_00: The overall effect size for anxiety reduction was small, at 0.37.
• 56:30
  SPEAKER_00: It improved slightly to 0.51 if the patients had a formal,
• 56:33
  SPEAKER_00: diagnosed clinical anxiety disorder rather than just generalized subclinical stress.
• 56:39
  SPEAKER_00: And they generally required higher total doses, greater than 2 grams a day, to see an effect.
• 56:45
  SPEAKER_01: Okay, so a high dose is required for anxiety.
• 56:47
  SPEAKER_01: But what is the paradox regarding the formulation?
• 56:51
  SPEAKER_00: Unlike depression,
• 56:52
  SPEAKER_00: the subgroup analysis for anxiety revealed that supplements with less
• 56:56
  SPEAKER_00: than 60% EPA worked significantly better.
• 56:59
  SPEAKER_00: The EPA major formulations that were so powerful for depression did not confer
• 57:05
  SPEAKER_00: a significant benefit for anxiety.
• 57:07
  SPEAKER_01: Wait, let me make sure I have this straight.
• 57:09
  SPEAKER_01: For depression, you desperately want high EPA, the anti-inflammatory fire extinguisher.
• 57:15
  SPEAKER_01: But for anxiety,
• 57:16
  SPEAKER_01: you want lower EPA,
• 57:18
  SPEAKER_01: meaning you are delivering a much higher ratio of DHA,
• 57:21
  SPEAKER_01: the structural flexible bricks.
• 57:22
  SPEAKER_01: Yes.
• 57:23
  SPEAKER_01: Why on earth would the brain require fundamentally different lipid ratios
• 57:27
  SPEAKER_01: to treat anxiety versus mood?
• 57:29
  SPEAKER_01: Let's speculate on the mechanics here.
• 57:31
  SPEAKER_00: It is a phenomenal neurobiological question.
• 57:35
  SPEAKER_00: We can robustly speculate based on the different pathologies.
• 57:39
  SPEAKER_00: Major depression appears to be heavily driven by systemic
• 57:43
  SPEAKER_00: and neuroinflammatory cascades, microglial activation, cytokine storms.
• 57:49
  SPEAKER_00: Hence, you need the potent anti-inflammatory EPA to quench the fire.
• 57:53
  SPEAKER_00: Right.
• 57:54
  SPEAKER_00: Anxiety,
• 57:55
  SPEAKER_00: however,
• 57:56
  SPEAKER_00: particularly in the hyperactive fear circuits of the amygdala,
• 57:59
  SPEAKER_00: might be far more related to receptor sensitivity,
• 58:02
  SPEAKER_00: membrane fluidity, and the rapid chaotic firing of ion channels.
• 58:07
  SPEAKER_01: And that structural integrity and fluidity requires the DHA.
• 58:10
  SPEAKER_00: Exactly.
• 58:11
  SPEAKER_00: If the neuronal membrane isn't perfectly fluid,
• 58:14
  SPEAKER_00: the GABA receptors,
• 58:16
  SPEAKER_00: which are the brain's primary calming inhibitory receptors,
• 58:20
  SPEAKER_00: cannot embed properly or function efficiently to regulate the chaotic signal.
• 58:24
  SPEAKER_00: You need the DHA bricks to physically smooth out the hyperactive signaling architecture.
• 58:30
  SPEAKER_01: That makes perfect, elegant mechanical sense.
• 58:33
  SPEAKER_01: Depression is a fire.
• 58:34
  SPEAKER_01: Anxiety is a structural glitch.
• 58:37
  SPEAKER_01: Okay, what about our third major clinical population, children with ADHD?
• 58:42
  SPEAKER_00: We looked to a meta-analysis of eight RCTs in children and adolescents.
• 58:47
  SPEAKER_00: Overall,
• 58:47
  SPEAKER_00: we see small but statistically significant improvements in both inattention
• 58:51
  SPEAKER_00: and hyperactivity using omega-3s.
• 58:54
  SPEAKER_00: But once again, formulation is king.
• 58:57
  SPEAKER_01: Let me guess, EPA matters here too?
• 59:00
  SPEAKER_00: It does.
• 59:00
  SPEAKER_00: When the specific dose of EPA was strictly controlled to be greater than or equal
• 59:05
  SPEAKER_00: to 500 milligrams a day,
• 59:07
  SPEAKER_00: Yielded a large,
• 59:08
  SPEAKER_00: robust effect size, specifically on the domain of hyperactivity, an SMD of 0.81.
• 59:15
  SPEAKER_01: An SMD of 0.81 just for providing adequate lipid architecture.
• 59:21
  SPEAKER_01: That is a massive non-pharmacological tool for a child struggling
• 59:25
  SPEAKER_01: to physically sit still in a classroom setting.
• 59:28
  SPEAKER_01: But we have to be intellectually honest in this deep dive.
• 59:30
  SPEAKER_01: We've talked exclusively about the successes and the high effect sizes.
• 59:35
  SPEAKER_01: We must look at the dark side of the ledger.
• 59:37
  SPEAKER_01: Where did Omega-3s completely fail to show efficacy?
• 59:40
  SPEAKER_00: The data is equally clear on their failures.
• 59:43
  SPEAKER_00: They failed completely in Autism Spectrum Disorder, or ASD.
• 59:47
  SPEAKER_00: A rigorous meta-analysis of five RCTs found absolutely zero improvement in
• 59:52
  SPEAKER_00: the core defining symptoms of autism.
• 59:54
  SPEAKER_00: Irritability, stereotypy, the repetitive movements, or inappropriate speech.
• 59:59
  SPEAKER_01: Zero improvement.
• 1:00:01
  SPEAKER_00: Zero.
• 1:00:02
  SPEAKER_00: The only metric that showed a tiny statistical improvement was a parent-rated scale
• 1:00:07
  SPEAKER_00: for lethargy,
• 1:00:08
  SPEAKER_00: which is highly subjective,
• 1:00:09
  SPEAKER_00: prone to placebo by proxy,
• 1:00:11
  SPEAKER_00: and critically was not matched by blinded clinician ratings.
• 1:00:15
  SPEAKER_01: So, to be clear, omega-3s are not a treatment for the core neurological pathology of autism.
• 1:00:20
  SPEAKER_00: Correct.
• 1:00:21
  SPEAKER_00: They also failed completely and utterly in Alzheimer's disease.
• 1:00:25
  SPEAKER_00: A meta-analysis of six RCTs involving nearly 800 patients
• 1:00:29
  SPEAKER_00: with established Alzheimer's,
• 1:00:30
  SPEAKER_00: there was zero improvement in cognitive deterioration,
• 1:00:34
  SPEAKER_00: memory retention, or neuropsychiatric symptoms like agitation.
• 1:00:38
  SPEAKER_01: And why do you think that is?
• 1:00:40
  SPEAKER_00: The biological reality is that once the profound,
• 1:00:43
  SPEAKER_00: widespread amyloid and tau-driven neurodegeneration of Alzheimer's has set in,
• 1:00:48
  SPEAKER_00: supplying fresh lipids cannot possibly rebuild the destroyed,
• 1:00:51
  SPEAKER_00: atrophied brain architecture.
• 1:00:53
  SPEAKER_01: A sobering but necessary reality check.
• 1:00:56
  SPEAKER_00: But what about the phase before Alzheimer's?
• 1:00:58
  SPEAKER_00: What about mild cognitive impairment,
• 1:01:01
  SPEAKER_00: or MCI, where the architecture is fraying but not yet destroyed?
• 1:01:06
  SPEAKER_01: There we see a legitimate glimmer of hope.
• 1:01:09
  SPEAKER_01: A review of 15 RCTs in patients with mild cognitive impairment showed small
• 1:01:14
  SPEAKER_01: but statistically significant consistent improvements in memory,
• 1:01:18
  SPEAKER_01: an SMD of 0.31, and executive function, an SMD of 0.19.
• 1:01:23
  SPEAKER_00: With which formulation?
• 1:01:25
  SPEAKER_01: These trials utilized mixed formulations of both EPA and DHA.
• 1:01:30
  SPEAKER_01: It is a small desk lamp of an effect size,
• 1:01:32
  SPEAKER_01: but when a patient and their family are facing the terrifying precipice
• 1:01:36
  SPEAKER_01: of cognitive decline, any light that delays the progression is immensely welcome.
• 1:01:41
  SPEAKER_01: So we have thoroughly explored the core biology of these crucial missing elements.
• 1:01:45
  SPEAKER_01: The sunlight-driven,
• 1:01:46
  SPEAKER_01: stress-regulating paradox of vitamin D,
• 1:01:49
  SPEAKER_01: the myelin-destroying,
• 1:01:50
  SPEAKER_01: masquerading borderline trap of vitamin B12,
• 1:01:53
  SPEAKER_01: The complex genetic baton pass of folate in the methylation cycle,
• 1:01:58
  SPEAKER_01: and the highly specific ratio-dependent lipid ledger of omega-3s.
• 1:02:03
  SPEAKER_01: It's time for us to bring all of this immense data together.
• 1:02:06
  SPEAKER_01: Let's integrate this into a cohesive framework of clinical reasoning.
• 1:02:10
  SPEAKER_00: The overarching theme that synthesizes this entire deep dive,
• 1:02:13
  SPEAKER_00: the singular message to take away,
• 1:02:16
  SPEAKER_00: is that we can no longer practice lazy cookbook psychiatry
• 1:02:19
  SPEAKER_00: with nutritional supplements.
• 1:02:21
  SPEAKER_01: Right, no generic multivitamins.
• 1:02:23
  SPEAKER_00: No, you cannot just hand out generic,
• 1:02:25
  SPEAKER_00: unformulated multivitamin recipes to every patient who reports low mood.
• 1:02:30
  SPEAKER_00: We are formally moving away from the outdated paradigm of nutrients
• 1:02:33
  SPEAKER_00: as alternative complementary medicine and stepping firmly into
• 1:02:37
  SPEAKER_00: the highly rigorous era of nutrients as precision biochemical adjuncts.
• 1:02:42
  SPEAKER_01: Precision biochemical adjuncts.
• 1:02:45
  SPEAKER_01: That phrasing perfectly captures the evolution of the science.
• 1:02:48
  SPEAKER_01: So how do we build a practical matrix of application?
• 1:02:51
  SPEAKER_01: How does the listener actually use this information tomorrow morning in the clinic?
• 1:02:56
  SPEAKER_00: We can neatly divide our clinical approach
• 1:02:58
  SPEAKER_00: into two distinct biologically sound strategies,
• 1:03:02
  SPEAKER_00: test and replace and targeted augmentation.
• 1:03:05
  SPEAKER_01: Let's break down the rules for test and replace.
• 1:03:08
  SPEAKER_00: This paradigm applies specifically to vitamin D and vitamin B12.
• 1:03:13
  SPEAKER_00: You do not ever use these as blind empiric psychiatric drugs.
• 1:03:17
  SPEAKER_00: You treat them as biological prerequisites.
• 1:03:20
  SPEAKER_00: You test the patient for deficiency.
• 1:03:22
  SPEAKER_00: If the patient presenting with depression, ADHD,
• 1:03:26
  SPEAKER_00: or cognitive symptoms is biochemically low,
• 1:03:28
  SPEAKER_00: you replace the nutrient to normalize their baseline.
• 1:03:31
  SPEAKER_01: And avoid the traps.
• 1:03:33
  SPEAKER_00: Yes, you must successfully navigate the specific clinical traps we discussed.
• 1:03:38
  SPEAKER_00: For vitamin D, the trap is the very real danger of fat-soluble toxicity and hypercalcemia.
• 1:03:44
  SPEAKER_00: You do not guess.
• 1:03:46
  SPEAKER_00: You test the 25 OHD level and follow the Endocrine Society guidelines.
• 1:03:51
  SPEAKER_01: And for B12?
• 1:03:52
  SPEAKER_00: For vitamin B12, the trap is the deceptive borderline laboratory limits.
• 1:03:57
  SPEAKER_00: You must utilize the methylmalonic acid test,
• 1:04:00
  SPEAKER_00: the MMA, to hunt down disguised functional deficiencies.
• 1:04:04
  SPEAKER_00: And remember that high-dose oral replacement of 1,000 to 2,000 micrograms is
• 1:04:09
  SPEAKER_00: a highly effective painless alternative to injections.
• 1:04:12
  SPEAKER_01: Test, safely replace, and remove the biological barrier to healing.
• 1:04:17
  SPEAKER_01: Got it.
• 1:04:18
  SPEAKER_01: And what are the rules for targeted augmentation?
• 1:04:22
  SPEAKER_00: This paradigm applies to folate and omega-3 fatty acids.
• 1:04:26
  SPEAKER_00: Here, we are not necessarily fixing a baseline deficiency.
• 1:04:30
  SPEAKER_00: We are using the nutrient much more like
• 1:04:32
  SPEAKER_00: a targeted therapeutic pharmacological agent to aggressively push
• 1:04:36
  SPEAKER_00: a specific sluggish biochemical pathway.
• 1:04:39
  SPEAKER_01: Right.
• 1:04:40
  SPEAKER_00: For folate,
• 1:04:41
  SPEAKER_00: we use the active L-methylfolate to drive remission in stubborn depression,
• 1:04:45
  SPEAKER_00: keeping that phenomenal NNT of 8 in mind.
• 1:04:48
  SPEAKER_00: But we must remain highly vigilant about the 15-week timeline limit and
• 1:04:52
  SPEAKER_00: the severe risk of triggering agitation or mania with a high 15 milligram dose.
• 1:04:58
  SPEAKER_01: And for omega-3s, the absolute rule of targeted augmentation is that formulation is everything.
• 1:05:04
  SPEAKER_00: Exactly.
• 1:05:05
  SPEAKER_00: You must read the label.
• 1:05:07
  SPEAKER_00: For major depression, we want to quench the inflammatory fire.
• 1:05:10
  SPEAKER_00: We demand an EPA major formulation,
• 1:05:13
  SPEAKER_00: 60% or more EPA, dosed up to a gram a day to capture that massive 1.03 effect size.
• 1:05:20
  SPEAKER_01: And for anxiety?
• 1:05:21
  SPEAKER_00: For clinical anxiety, we flip the script to stabilize the structural architecture.
• 1:05:25
  SPEAKER_00: We want less than 60% EPA, delivering more DHEA at higher overall doses.
• 1:05:32
  SPEAKER_00: And for the hyperactivity domain in pediatric ADHD,
• 1:05:36
  SPEAKER_00: we ensure targeted delivery of at least 500 milligrams of EPA daily.
• 1:05:41
  SPEAKER_01: It is incredibly elegant when you lay the matrix out like that.
• 1:05:44
  SPEAKER_01: It deeply respects the underlying cellular biology
• 1:05:47
  SPEAKER_01: without ever overpromising miraculous unearned results.
• 1:05:51
  SPEAKER_00: That synthesis is the very essence of good, rigorous psychiatric practice.
• 1:05:56
  SPEAKER_01: All right, listeners, it is time to stress test your new mental models.
• 1:06:00
  SPEAKER_01: We are going to run through five rapid-fire clinical case vignettes based directly
• 1:06:05
  SPEAKER_01: on the nuance of the textbook chapter.
• 1:06:07
  SPEAKER_01: I will present the clinical scenario.
• 1:06:09
  SPEAKER_01: I want you to mentally lock in your diagnostic or therapeutic next move,
• 1:06:13
  SPEAKER_01: and then our expert will reveal the evidence-based clinical reasoning.
• 1:06:17
  SPEAKER_01: Ready?
• 1:06:18
  SPEAKER_00: Let's run the cases.
• 1:06:19
  SPEAKER_01: Case one.
• 1:06:21
  SPEAKER_01: You are evaluating a 35-year-old patient who presents with an insidious onset
• 1:06:25
  SPEAKER_01: of depressive symptoms and noticeable cognitive slowing.
• 1:06:29
  SPEAKER_01: You order a standard blood panel.
• 1:06:32
  SPEAKER_01: Their serum vitamin B12 level comes back at 310 pgml.
• 1:06:36
  SPEAKER_01: The lab report highlights this value in green, labeling it as normal.
• 1:06:40
  SPEAKER_01: Based on our deep dive,
• 1:06:42
  SPEAKER_01: what is your immediate next move to ensure you aren't missing
• 1:06:45
  SPEAKER_01: a disguised presentation?
• 1:06:47
  SPEAKER_00: Your next move is to entirely distrust that normal label and immediately order
• 1:06:52
  SPEAKER_00: a test for methylmalonic acid or MMA.
• 1:06:55
  SPEAKER_00: You must remember the borderline trap.
• 1:06:58
  SPEAKER_00: Total serum B12 levels anywhere between 200 and 400 pGML can easily hide
• 1:07:02
  SPEAKER_00: a severe functional deficiency at the cellular level.
• 1:07:06
  SPEAKER_00: An elevated MMA,
• 1:07:07
  SPEAKER_00: specifically greater than 0.271 micromoles per liter,
• 1:07:11
  SPEAKER_00: is your highly reliable definitive cutoff to confirm that
• 1:07:14
  SPEAKER_00: the enzymatic pathway is stalled and the patient is truly deficient.
• 1:07:19
  SPEAKER_01: Excellent.
• 1:07:20
  SPEAKER_01: Case 2.
• 1:07:21
  SPEAKER_01: You have diagnosed a patient with severe major depressive disorder.
• 1:07:25
  SPEAKER_01: They are interested in adjunctive nutritional interventions and ask you to recommend
• 1:07:29
  SPEAKER_01: a specific fish oil supplement.
• 1:07:32
  SPEAKER_01: To give them the absolute best chance at experiencing
• 1:07:35
  SPEAKER_01: that massive 1.03 effect size we discussed,
• 1:07:38
  SPEAKER_01: what specific instructions do you give them regarding the formulation on the bottle?
• 1:07:43
  SPEAKER_00: You instruct them to ignore the marketing on the front of the bottle,
• 1:07:46
  SPEAKER_00: turn it around to the nutritional panel, and calculate the ratio.
• 1:07:49
  SPEAKER_00: For depression, you are treating neuroinflammation, so you need the fire extinguisher.
• 1:07:54
  SPEAKER_01: The EPA.
• 1:07:54
  SPEAKER_00: Yes.
• 1:07:55
  SPEAKER_00: You must instruct them to purchase an EPA major formulation,
• 1:08:00
  SPEAKER_00: meaning the ratio must be strictly greater than or equal to 60% EPA,
• 1:08:04
  SPEAKER_00: dosed up to 1 gram a day.
• 1:08:06
  SPEAKER_00: You remind them that while a lower EPA ratio is curiously better for anxiety,
• 1:08:11
  SPEAKER_00: the high EPA ratio is non-negotiable for yielding
• 1:08:13
  SPEAKER_00: the largest therapeutic effect size for depressive symptoms.
• 1:08:17
  SPEAKER_01: Case 3.
• 1:08:18
  SPEAKER_01: You are supervising a junior psychiatry trainee.
• 1:08:21
  SPEAKER_01: They are managing a complex case of treatment-resistant depression in a 28-year-old patient.
• 1:08:26
  SPEAKER_01: The trainee enthusiastically suggests adding 15 milligrams of active L-methylfolate
• 1:08:31
  SPEAKER_01: to the patient's existing medication regimen to push the methylation cycle.
• 1:08:36
  SPEAKER_01: You agree this is an evidence-based strategy,
• 1:08:38
  SPEAKER_01: but what specific severe adverse effect must you instruct the trainee to warn
• 1:08:43
  SPEAKER_01: the patient about and monitor for over the coming weeks?
• 1:08:46
  SPEAKER_00: You must instruct the trainee to monitor vigilantly for severe irritability,
• 1:08:51
  SPEAKER_00: psychomotor agitation, and signs of emerging mania.
• 1:08:54
  SPEAKER_00: You explained that by dropping 50 milligrams of active folate into the system,
• 1:08:58
  SPEAKER_00: they are aggressively revving the neurotransmitter engine and flooding the brain
• 1:09:02
  SPEAKER_00: with the capacity to synthesize dopamine and norepinephrine.
• 1:09:05
  SPEAKER_00: If the patient's regulatory system is unstable,
• 1:09:08
  SPEAKER_00: cases of triggered mania have been documented in the literature.
• 1:09:12
  SPEAKER_01: Be careful with the biological accelerator.
• 1:09:14
  SPEAKER_01: Case 4.
• 1:09:16
  SPEAKER_01: A 10-year-old boy is receiving standard methylphenidate therapy for his ADHD,
• 1:09:21
  SPEAKER_01: but he still struggles significantly with the hyperactivity domain in the classroom.
• 1:09:25
  SPEAKER_01: The parents have read about nutritional psychiatry online and want
• 1:09:28
  SPEAKER_01: to immediately start giving him high doses of vitamin D.
• 1:09:31
  SPEAKER_01: Before you endorse adding this neurosteroid to his regimen,
• 1:09:35
  SPEAKER_01: what specific prerequisite must you establish based on the subgroup analyses of
• 1:09:40
  SPEAKER_01: the meta-trials?
• 1:09:41
  SPEAKER_00: You must establish his baseline vitamin D status via a 25-OHD blood test
• 1:09:47
  SPEAKER_00: before allowing supplementation.
• 1:09:49
  SPEAKER_00: You explained to the parents that the crucial subgroup analysis unequivocally showed
• 1:09:53
  SPEAKER_00: that children only experienced improvements in ADHD symptoms
• 1:09:57
  SPEAKER_00: if they actually had deficient or insufficient baseline levels to begin with.
• 1:10:01
  SPEAKER_01: Otherwise, it doesn't help.
• 1:10:02
  SPEAKER_00: Exactly.
• 1:10:03
  SPEAKER_00: If his blood work shows his levels are already sufficient,
• 1:10:06
  SPEAKER_00: adding extra vitamin D will not improve his hyperactivity.
• 1:10:10
  SPEAKER_00: And since it is fat soluble, it only introduces the unnecessary risk of hypercalcemia.
• 1:10:16
  SPEAKER_00: You cannot build a stronger house by dumping extra bricks on a finished lawn.
• 1:10:20
  SPEAKER_01: And finally, case five.
• 1:10:22
  SPEAKER_01: An elderly patient under your care is diagnosed with a severe B12 deficiency driven
• 1:10:26
  SPEAKER_01: by longstanding pernicious anemia,
• 1:10:28
  SPEAKER_01: meaning they lack intrinsic factor for gastric absorption.
• 1:10:31
  SPEAKER_01: They're absolutely terrified of needles and adamantly refuse to comply with
• 1:10:36
  SPEAKER_01: the standard regimen of intramuscular B12 injections.
• 1:10:40
  SPEAKER_01: What does the highest level of clinical evidence,
• 1:10:42
  SPEAKER_01: specifically the 2018 Cochrane Review,
• 1:10:45
  SPEAKER_01: suggest you can confidently offer them as an alternative?
• 1:10:48
  SPEAKER_00: You can confidently offer them daily high-dose oral supplementation.
• 1:10:52
  SPEAKER_00: The Cochran Review established clear evidence that a massive oral dose of 1,000
• 1:10:57
  SPEAKER_00: to 2,000 micrograms daily is just as efficacious at normalizing serum levels
• 1:11:01
  SPEAKER_00: and resolving symptoms as the painful intramuscular injections.
• 1:11:06
  SPEAKER_01: Because of the passive diffusion.
• 1:11:07
  SPEAKER_00: Yes.
• 1:11:08
  SPEAKER_00: You explained that even with their broken active absorption mechanism,
• 1:11:11
  SPEAKER_00: flooding the gut with that high dose ensures enough B12 crosses
• 1:11:14
  SPEAKER_00: the mucosal barrier via passive diffusion to replete their systemic stores.
• 1:11:19
  SPEAKER_01: Brilliant clinical reasoning.
• 1:11:20
  SPEAKER_01: If you nailed the mechanics of those five cases,
• 1:11:22
  SPEAKER_01: you have successfully internalized the conceptual models we set out to build today.
• 1:11:27
  SPEAKER_01: To all our listeners,
• 1:11:28
  SPEAKER_01: we highly,
• 1:11:29
  SPEAKER_01: highly encourage you to direct yourselves back to chapter 30.5 of Kaplan
• 1:11:33
  SPEAKER_01: and Satic's comprehensive textbook of psychiatry.
• 1:11:36
  SPEAKER_01: The detailed epidemiological tables and
• 1:11:38
  SPEAKER_01: the highly specific endocrine society dosing guidelines contained within
• 1:11:42
  SPEAKER_01: that text are invaluable,
• 1:11:45
  SPEAKER_01: non-negotiable references for your daily clinical practice.
• 1:11:48
  SPEAKER_00: It is an intensely dense chapter of biochemistry,
• 1:11:50
  SPEAKER_00: but as we have thoroughly explored today,
• 1:11:53
  SPEAKER_00: mastering the mechanics of these missing biological elements can drastically alter
• 1:11:57
  SPEAKER_00: a patient's entire trajectory of healing.
• 1:12:00
  SPEAKER_01: It absolutely can.
• 1:12:01
  SPEAKER_01: And before we close out this deep dive,
• 1:12:03
  SPEAKER_01: I want to leave you with a final,
• 1:12:05
  SPEAKER_01: slightly provocative thought to mull over as you see patients this week.
• 1:12:08
  SPEAKER_01: We spent the last hour strictly talking about these molecules as adjuncts
• 1:12:12
  SPEAKER_01: and supplements,
• 1:12:14
  SPEAKER_01: words that inherently imply they are secondary,
• 1:12:16
  SPEAKER_01: lesser additions to real pharmacological medicine.
• 1:12:19
  SPEAKER_00: Right.
• 1:12:20
  SPEAKER_01: But as we continue to rapidly map the human genome,
• 1:12:23
  SPEAKER_01: as we uncover more widespread genetic variants like MTHFR and MTR,
• 1:12:27
  SPEAKER_01: and as we increasingly understand the exact uncompromising structural requirements
• 1:12:32
  SPEAKER_01: of the brain's lipid ledgers and myelin sheaths, well,
• 1:12:36
  SPEAKER_01: will the clinical psychiatry of the year 2050 even bother to distinguish between
• 1:12:40
  SPEAKER_01: a nutrient and a pharmaceutical?
• 1:12:42
  SPEAKER_01: Or will we simply view every single evidence-based intervention we make as
• 1:12:47
  SPEAKER_01: a precisely targeted structural repair of the mind?
• 1:12:51
  SPEAKER_01: Think about it.
• 1:12:52
  SPEAKER_01: We'll see you next time.